Methods and systems for presenting a combination treatment

ABSTRACT

Methods, computer program products, and systems are described that include accepting an indication of a schedule for administration of a bioactive agent to an individual and presenting an indication of an artificial sensory experience at least partly based on the accepting an indication of the schedule for administration of the bioactive agent to the individual.

CROSS-REFERENCE TO RELATED APPLICATIONS

The present application is related to and claims the benefit of theearliest available effective filing date(s) from the following listedapplication(s) (the “Related Applications”) (e.g., claims earliestavailable priority dates for other than provisional patent applicationsor claims benefits under 35 USC §119(e) for provisional patentapplications, for any and all parent, grandparent, great-grandparent,etc. applications of the Related Application(s)).

RELATED APPLICATIONS

-   -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION TREATMENT        SELECTION METHODS AND SYSTEMS, naming Roderick A. Hyde;        Muriel Y. Ishikawa; Eric C. Leuthardt; Royce A. Levien;        Robert W. Lord; Mark A. Malamud; Elizabeth A. Sweeney; Lowell L.        Wood, Jr.; and Victoria Y. H. Wood as inventors, filed Apr. 24,        2008, application Ser. No. 12/150,122, which is currently        co-pending, or is an application of which a currently co-pending        application is entsitled to the benefits of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION TREATMENT        MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed May 13,        2008, application Ser. No. 12/152,266, now abandoned.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION TREATMENT        ALTERATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed May 21,        2008, application Ser. No. 12/154,275, now U.S. Pat. No.        7,974,787.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION THERAPEUTIC        PRODUCTS AND SYSTEMS, naming RODERICK A. HYDE; MURIEL Y.        ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN; ROBERT W. LORD;        MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L. WOOD, JR.; AND        VICTORIA Y. H. WOOD as inventors, filed May 30, 2008,        application Ser. No. 12/156,440, which is currently co-pending,        or is an application of which a currently co-pending application        is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled SIDE EFFECT AMELIORATING        COMBINATION THERAPEUTIC PRODUCTS AND SYSTEMS, naming RODERICK A.        HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 5,        2008, application Ser. No. 12/156,949, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filling date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION TREATMENT        MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 6,        2008, application Ser. No. 12/157,160, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the fililng date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION TREATMENT        SELECTION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 13,        2008, application Ser. No. 12/157,922, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION TREATMENT        MODIFICATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 13,        2008, application Ser. No. 12/157,989, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled COMBINATION TREATMENT        ALTERATION METHODS AND SYSTEMS, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jun. 19,        2008, application Ser. No. 12/214,547, now U.S. Pat. No.        7,801,696.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 3,        2008, application Ser. No. 12/217,509, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 7,        2008, application Ser. No. 12/217,620, now U.S Pat. No.        8,606,592.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 15,        2008, application Ser. No. 12/218,503, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 16,        2008, application Ser. No. 12/218,627, which is currently        co-pendig, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled SYSTEMS AND APPARATUS FOR        MEASURING A BIOACTIVE AGENT EFFECT, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Jul. 25,        2008, application Ser. No. 12/220,706, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MODIFYING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Aug. 22,        2008, application Ser. No. 12/229,531, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MODIFYING BIOACTIVE AGENT USE, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Aug. 25,        2008, application Ser. No. 12/229,612, now abandoned.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        DETECTING A BIOACTIVE AGENT EFFECT, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Sep. 12,        2008, application Ser. No. 12/283,619, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        DETECTING A BIOACTIVE AGENT EFFECT, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Sep. 15,        2008, application Ser. No. 12/283,742, now U.S Pat. No.        8,615,407.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING AND MODIFYING A COMBINATION TREATMENT, naming        RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT;        ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A.        SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as        inventors, filed Sep. 30, 2008, application Ser. No. 12/286,751,        which is currently co-pending, or is an application of which a        currently co-pending application is entitled to the benefit of        the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING AND MODIFYING A COMBINATION TREATMENT, naming        RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT;        ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A.        SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as        inventors, filed Sep. 30, 2008, application Ser. No. 12/286,730,        which is currently co-pending, or is an application of which a        currently co-pending application is entitled to the benefit of        the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING AND MODIFYING A COMBINATION TREATMENT, naming        RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT;        ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A.        SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as        inventors, filed Oct. 10, 2008, application Ser. No. 12/287,686,        which is currently co-pending, or is an application of which a        currently co-pending application is entitled to the benefit of        the filling date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        MONITORING AND MODIFYING A COMBINATION TREATMENT, naming        RODERICK A. HYDE; MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT;        ROYCE A. LEVIEN; ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A.        SWEENEY; LOWELL L. WOOD, JR.; AND VICTORIA Y. H. WOOD as        inventors, filed Oct. 14, 2008, application Ser. No. 12/287,886,        which is currently co-pending, or is an application of which a        currently co-pending application is entitled to the benefit of        the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        PRESENTING A COMBINATION TREATMENT, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Oct. 28,        2008, application Ser. No. 12/290,227, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.    -   For purposes of the USPTO extra-statutory requirements, the        present application constitutes a continuation-in-part of United        States Patent Application entitled METHODS AND SYSTEMS FOR        PRESENTING A COMBINATION TREATMENT, naming RODERICK A. HYDE;        MURIEL Y. ISHIKAWA; ERIC C. LEUTHARDT; ROYCE A. LEVIEN;        ROBERT W. LORD; MARK A. MALAMUD; ELIZABETH A. SWEENEY; LOWELL L.        WOOD, JR.; AND VICTORIA Y. H. WOOD as inventors, filed Oct. 29,        2008, application Ser. No. 12/290,456, which is currently        co-pending, or is an application of which a currently co-pending        application is entitled to the benefit of the filing date.

The United States Patent Office (USPTO) has published a notice to theeffect that the USPTO's computer programs require that patent applicantsreference both a serial number and indicate whether an application is acontinuation or continuation-in-part. Stephen G. Kunin, Benefit ofPrior-Filed Application, USPTO Official Gazette Mar. 18, 2003, availableat http://www.uspto.gov/web/offices/com/sol/og/2003/week11/patbene.htm.The present Applicant Entity (hereinafter “Applicant”) has providedabove a specific reference to the application(s) from which priority isbeing claimed as recited by statute. Applicant understands that thestatute is unambiguous in its specific reference language and does notrequire either a serial number or any characterization, such as“continuation” or “continuation-in-part,” for claiming priority to U.S.patent applications. Notwithstanding the foregoing, Applicantunderstands that the USPTO's computer programs have certain data entryrequirements, and hence Applicant is designating the present applicationas a continuation-in-part of its parent applications as set forth above,but expressly points out that such designations are not to be construedin any way as any type of commentary and/or admission as to whether ornot the present application contains any new matter in addition to thematter of its parent application(s).

All subject matter of the Related Applications and of any and allparent, grandparent, great-grandparent, etc. applications of the RelatedApplications is incorporated herein by reference to the extent suchsubject matter is not inconsistent herewith.

TECHNICAL FIELD

This description relates to methods and systems for combining abioactive agent with an artificial sensory experience.

SUMMARY

In one aspect, a method includes but is not limited to accepting anindication of a schedule for administration of a bioactive agent to anindividual and presenting an indication of an artificial sensoryexperience at least partly based on the accepting an indication of theschedule for administration of the bioactive agent to the individual. Inaddition to the foregoing, other method aspects are described in theclaims, drawings, and text forming a part of the present disclosure.

In one or more various aspects, related systems include but are notlimited to circuitry and/or programming for effecting theherein-referenced method aspects; the circuitry and/or programming canbe virtually any combination of hardware, software, and/or firmwareconfigured to effect the herein-referenced method aspects depending uponthe design choices of the system designer.

In one aspect, a method includes but is not Limited to accepting anindication of at least one of a pharmacokinetic or pharmacodynamicprofile of a bioactive agent and an indication of a schedule foradministration of the bioactive agent to an individual and presenting anindication of an artificial sensory experience at least partly based onthe accepting an indication of the at least one of a pharmacokinetic orpharmacodynamic profile of the bioactive agent and the indication of theschedule for administration of the bioactive agent to the individual. Inaddition to the foregoing, other method aspects are described in theclaims, drawings, and text forming a part of the present disclosure.

In one or more various aspects, related systems include but are notlimited to circuitry and/or programming for effecting theherein-referenced method aspects; the circuitry and/or programming canbe virtually any combination of hardware, software, and/or firmwareconfigured to effect the herein-referenced method aspects depending uponthe design choices of the system designer.

In one aspect, a method includes but is not limited to accepting anindication of a bioactive agent administration for an individual,determining at least one of a pharmacokinetic or pharmacodynamic profileof the bioactive agent, and/or presenting an indication of an artificialsensory experience at least partly based on the accepting an indicationof the at least one of a pharmacokinetic or pharmacodynamic profile ofthe bioactive agent and the indication of the schedule foradministration of the bioactive agent to the individual. In addition tothe foregoing, other method aspects are described in the claims,drawings, and text forming a part of the present disclosure.

In one or more various aspects, related systems include but are notlimited to circuitry and/or programming for effecting theherein-referenced method aspects; the circuitry and/or programming canbe virtually any combination of hardware, software, and/or firmwareconfigured to effect the herein-referenced method aspects depending uponthe design choices of the system designer.

In one aspect, a method includes but is not limited to accepting anindication of at least one bioactive agent and an indication of aschedule for administration of the bioactive agent to an individualand/or presenting an indication of an artificial sensory experience atleast partly based on at least one of a pharmacokinetic profile orpharmacodynamic profile of the bioactive agent and the indication of theschedule for administration of the bioactive agent to the individual. Inaddition to the foregoing, other method aspects are described in theclaims, drawings, and text forming a part of the present disclosure.

In one or more various aspects, related systems include but are notlimited to circuitry and/or programming for effecting theherein-referenced method aspects; the circuitry and/or programming canbe virtually any combination of hardware, software, and/or firmwareconfigured to effect the herein-referenced method aspects depending uponthe design choices of the system designer.

In one aspect, a system includes but is not limited to means foraccepting an indication of a schedule for administration of a bioactiveagent to an individual and means for presenting an indication of anartificial sensory experience at least partly based on the accepting anindication of the schedule for administration of the bioactive agent tothe individual. In addition to the foregoing, other method aspects aredescribed in the claims, drawings, and text forming a part of thepresent disclosure.

In one aspect, a system includes but is not limited to means foraccepting an indication of at least one of a pharmacokinetic orpharmacodynamic profile of a bioactive agent and an indication of aschedule for administration of the bioactive agent to an individual andmeans for presenting an indication of an artificial sensory experienceat least partly based on the accepting an indication of the at least oneof a pharmacokinetic or pharmacodynamic profile of the bioactive agentand the indication of the schedule for administration of the bioactiveagent to the individual. In addition to the foregoing, other methodaspects are described in the claims, drawings, and text forming a partof the present disclosure.

In one aspect, a system includes but is not limited to means foraccepting an indication of a bioactive agent administration for anindividual, means for determining at least one of a pharmacokinetic orpharmacodynamic profile of the bioactive agent, and/or means forpresenting an indication of an artificial sensory experience at leastpartly based on the accepting an indication of the at least one of apharmacokinetic or pharmacodynamic profile of the bioactive agent andthe indication of the schedule for administration of the bioactive agentto the individual. In addition to the foregoing, other method aspectsare described in the claims, drawings, and text forming a part of thepresent disclosure.

In one aspect, a system includes but is not limited to means foraccepting an indication of at least one bioactive agent and anindication of a schedule for administration of the bioactive agent to anindividual and means for presenting an indication of an artificialsensory experience at least partly based on at least one of apharmacokinetic profile or pharmacodynamic profile of the bioactiveagent and the indication of the schedule for administration of thebioactive agent to the individual. In addition to the foregoing, othermethod aspects are described in the claims, drawings, and text forming apart of the present disclosure.

In one aspect, a system includes but is not limited to circuitry foraccepting an indication of a schedule for administration of a bioactiveagent to an individual and circuitry for presenting an indication of anartificial sensory experience at least partly based on the accepting anindication of the schedule for administration of the bioactive agent tothe individual. In addition to the foregoing, other method aspects aredescribed in the claims, drawings, and text forming a part of thepresent disclosure.

In one aspect, a computer program product includes but is not limited toa signal-bearing medium bearing one or more instructions for acceptingan indication of a schedule for administration of a bioactive agent toan individual, and one or more instructions for presenting an indicationof an artificial sensory experience at least partly based on theaccepting an indication of the schedule for administration of thebioactive agent to the individual. In addition to the foregoing, othermethod aspects are described in the claims, drawings, and text forming apart of the present disclosure.

In one aspect, a system includes but is not limited to a computingdevice and instructions that when executed on the computing device causethe computing device to accept an indication of a schedule foradministration of a bioactive agent to an individual and present anindication of an artificial sensory experience at least partly based onthe accepting an indication of the schedule for administration of thebioactive agent to the individual. In addition to the foregoing, othermethod aspects are described in the claims, drawings, and text forming apart of the present disclosure.

The foregoing is a summary and thus may contain simplifications,generalizations, inclusions, and/or omissions of detail; consequently,those skilled in the art will appreciate that the summary isillustrative only and is NOT intended to be in any way limiting. Otheraspects, features, and advantages of the devices and/or processes and/orother subject matter described herein will become apparent in theteachings set forth herein.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 2 illustrates an operational flow representing example operationsrelated to selecting a combination of at least one prescriptionmedication and at least one artificial sensory experience.

FIG. 3 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 4 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 5 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 6 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 7 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 8 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 9 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 10 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 11 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 12 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 13 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 14 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 15 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 16 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 17 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 18 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 19 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 20 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 21 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 22 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 23 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 24 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 25 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 26 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 27 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 28 illustrates an alternative embodiment of the operational flow ofFIG. 2.

FIG. 29 illustrates an operational flow representing example operationsrelated to selecting a combination of at least one prescriptionmedication and at least one artificial sensory experience.

FIG. 30 illustrates a computer program product related to selecting acombination of at least one prescription medication and at least oneartificial sensory experience.

FIG. 31 illustrates a system related to selecting a combination of atleast one prescription medication and at least one artificial sensoryexperience.

FIG. 32 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 33 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 34 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 35 illustrates an exemplary environment in which one or moretechnologies may be implemented.

FIG. 36 illustrates an operational flow representing example operationsrelated to presenting an indication of an artificial sensory experience.

FIG. 37 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 38 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 39 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 40 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 41 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 42 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 43 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 44 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 45 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 46 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 47 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 48 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 49 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 50 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 51 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 52 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 53 illustrates an alternative embodiment of the operational flow ofFIG. 36.

FIG. 54 illustrates a computer program product related to presenting anindication of an artificial sensory experience.

FIG. 55 illustrates a system related to presenting an indication of anartificial sensory experience.

DETAILED DESCRIPTION

In the following detailed description, reference is made to theaccompanying drawings, which form a part hereof. In the drawings,similar symbols typically identify similar components, unless contextdictates otherwise. The illustrative embodiments described in thedetailed description, drawings, and claims are not meant to be limiting.Other embodiments may be utilized, and other changes may be made,without departing from the spirit or scope of the subject matterpresented here.

FIG. 1 illustrates a system 100 for accepting at least one attribute ofat least one individual, querying at least one database at least partlybased on the at least one attribute, selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual, and presenting an indication of the at leastone prescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. The system 100 may include acceptor module 102,querier module 104, selector module 106, presenter module 108,implementer module 138, and/or modifier module 140. Acceptor module 102may receive attribute 120 from network storage 110, memory device 112,database entry 114, and/or user interface 116. User interface 116 mayreceive information from user 118. User 118 may include health careprovider 136. Querier module 104 may search database 122. Database 122may include medication database 124 and/or artificial sensory experiencedatabase 126. Presenter module 108 may present to health care provider128, output device 130, and/or individual 134. Output device 130 mayinclude mobile device 132. Modifier module 140 may include restrictormodule 142, granter module 144, alterer module 146, adder module 148,deleter module 150, and/or acceptor module 152. System 100 generallyrepresents instrumentality for accepting at least one attribute of atleast one individual, querying at least one database at least partlybased on the at least one attribute, selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual, and presenting an indication of the at leastone prescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. The operations of accepting at least oneattribute of at least one individual, querying at least one database atleast partly based on the at least one attribute, selecting from the atleast one database at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual, and presenting an indication of the at leastone prescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual may be accomplished electronically, such as witha set of interconnected electrical components, an integrated circuit,and/or a computer processor.

FIG. 2 illustrates an operational flow 200 representing exampleoperations related to accepting at least one attribute of at least oneindividual, querying at least one database at least partly based on theat least one attribute, selecting from the at least one database atleast one prescription medication and at least one artificial sensoryexperience to address the at least one attribute of at least oneindividual, and/or presenting an indication of the at least oneprescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. In FIG. 2 and in following figures that includevarious examples of operational flows, discussion and explanation may beprovided with respect to the above-described examples of FIG. 1, and/orwith respect to other examples and contexts. However, it should beunderstood that the operational flows may be executed in a number ofother environments and contexts, and/or in modified versions of FIG. 1.Also, although the various operational flows are presented in thesequence(s) illustrated, it should be understood that the variousoperations may be performed in other orders than those which areillustrated, or may be performed concurrently.

After a start operation, the operational flow 200 moves to an operation210. Operation 210 depicts accepting at least one attribute of at leastone individual. For example, as shown in FIG. 1, acceptor module 102 mayaccept at least one attribute of at least one individual. In oneinstance, acceptor module 102 can accept from a user 118 and a userinterface 116 an attribute 120 including an attribute of a personalhealth history associated with an individual named John Smith. In someinstances, acceptor module 102 may include a computer processor.

Then, operation 220 depicts querying at least one database at leastpartly based on the at least one attribute. For example, as shown inFIG. 1, querier module 104 may search at least one database at leastpartly based on the at least one attribute. In one example andcontinuing with the previous example, querier module 104 can search adatabase 122 including a medication database 124 and artificial sensoryexperience database 126 at least partly based on the attribute includingan attribute of a personal health history associated with an individualnamed John Smith. In some instances, querier module 104 may include acomputer processor.

Then, operation 230 depicts selecting from the at least one database atleast one prescription medication and at least one artificial sensoryexperience to address the at least one attribute of at least oneindividual. For example, as shown in FIG. 1, selector module 106 mayselect from the at least one database at least one prescriptionmedication and at least one artificial sensory experience to address theat least one attribute of at least one individual. In one instance andcontinuing with the previous example, selector module 106 can selectfrom a medication database 124 and artificial sensory experiencedatabase 126 a prescription medication and an artificial sensoryexperience for addressing the attribute 120 including an attribute of apersonal health history associated with an individual named John Smith.In some instances, selector module 106 may include a computer processor.

Then, operation 240 depicts presenting an indication of the at least oneprescription medication and the at least one artificial sensoryexperience at least partly based on the selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. For example, as shown in FIG. 1, presentermodule 108 may present the at least one prescription medication and theat least one artificial sensory experience at least partly based on thesearching at least one database at least partly based on the at leastone attribute. In one instance and continuing with the previous example,presenter module 108 can present to a medical professional theprescription medication and the artificial sensory experience based onsearching the medication database 124 and artificial sensory experiencedatabase 126 based on the at least one attribute 120 including anattribute of a personal health history associated with an individualnamed John Smith. In some instances, presenter module 108 may include acomputer processor.

FIG. 3 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 3 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 302.

Operation 302 illustrates accepting at least one physical enhancementgoal associated with the at least one individual. For example, as shownin FIG. 1, acceptor module 102 may accept from a database entry 114 atleast one physical enhancement goal associated with the at least oneindividual. In one instance and continuing with the above example,acceptor module 102 accepts from memory device 112 at least one physicalenhancement goal associated with an individual named John Smith. Aphysical enhancement goal may include a physical state and/or situationan individual may plan to achieve. Some examples of a physicalenhancement goal may include achieving a certain state of relaxation,reaching a certain body mass, maintaining a specific cholesterol level,achieving an athletic performance goal, and/or towering a blood pressurelevel. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 4 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 4 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 402, an operation 404, and/or anoperation 406.

Operation 402 illustrates accepting at least one physical attributeassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept from network storage 110 at leastone physical attribute associated with the at least one individual. Inone instance, acceptor module 102 can accept a physical attribute 120associated with a group of twenty individuals including an individualweight for each individual. A physical attribute may include anattribute that may be described and/or detected using senses, that hassubstance and/or a material existence, and/or that may be acted upon byphysical force. Some examples of a physical attribute may include abiochemical measurement such as blood sugar level, a smell, anappearance, a physiological measurement such as blood pressure, and/orskin conductivity. In some instances, acceptor module 102 may include acomputer processor.

Operation 404 illustrates accepting at least one physical symptomassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one physical symptomassociated with the at least one individual. In one example, acceptormodule 102 can accept from a user 118 and/or user interface 116 aphysical symptom including an indication of influenza such as a feverassociated with an individual named Mark White. A physical symptom mayinclude a manifestation, sign, and/or an indication of the presence of adisease and/or some other bodily disorder and/or abnormality. Someexamples of a physical symptom may include pain, swelling, fever, rash,and/or discoloration. In some instances, acceptor module 102 may includea computer processor.

Operation 406 illustrates accepting at least one of an indication or ameasurement of at least one of pain, hypertension, sweating, dizziness,lightheadedness, abnormal respiration, headache, fatigue, nausea, fever,abnormal heart rhythm, motor weakness, or abnormal heart rate. Forexample, as shown in FIG. 1, acceptor module 102 may accept from atleast one of an indication or a measurement of at least one of pain,high blood pressure, sweating, dizziness, lightheadedness, abnormalrespiration, headache, fatigue, nausea, fever, abnormal heart rhythm,motor weakness, or abnormal heart rate. In one example, acceptor module102 can accept an indication of pain and a measurement of high bloodpressure from network storage 110. Pain may include a sensation ofsomatic hurt or disorder and may include acute pain and/or chronic pain.Hypertension may include chronically elevated blood pressure and may beconsidered to be present when a person's systolic blood pressure isconsistently about 140 mm Hg or greater and/or their diastolic bloodpressure is consistently about 90 mm Hg or greater. Sweating may includethe excessive production and/or evaporation of fluid excreted by thesweat glands in the skin. Dizziness may include vertigo, disequilibrium,pre-syncope, and/or other balance disorders. Lightheadedness may includea sensation of dizziness and/or fainting. Abnormal respiration mayinclude atypical and/or pathological breathing patterns. Headache mayinclude pain in the head, neck, and/or upper back and may be a symptomof tension, migraine, dehydration, eye strain, sinus disorders, and/orlow blood sugar. Fatigue may include muscle weakness and/or lack ofstrength. Nausea may include the sensation of unease and/or discomfortin the stomach, often with the urge to vomit. Fever may include anincrease in internal body temperature to levels above normal. Abnormalheart rhythm may include inconsistent and/or irregular rhythmiccontractions in the heart such as sick sinus syndrome, atrialfibrillation, and/or atrial flutter. Motor weakness may include a lackof strength and/or function in the portion of the central nervous systeminvolved in movement. An abnormal heart rate may include an irregularheart contraction frequency such as bradycardia, tachycardia or thelike. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 5 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 5 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 502, and/or an operation 504.Further, operation 502 illustrates accepting at least one physicalimpairment associated with the at least one individual. For example, asshown in FIG. 1, acceptor module 102 may accept at least one physicalimpairment associated with the at least one individual from a user 118and a user interface 116. In one instance, acceptor module 102 accepts aphysical impairment including a bodily impairment associated with anindividual named Fred Johnson from a user 118 and/or a user interface116. A physical impairment may include a condition or function judged tobe significantly impaired relative to the usual standard of anindividual of their group and may include physical impairment, sensoryimpairment, and/or disease. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 504 illustrates accepting at least one of a disease, anillness, or a bodily impairment. For example, as shown in FIG. 1,acceptor module 102 may accept at least one of a disease, an illness, ora bodily impairment. In one example, acceptor module 102 accepts anindication of a disease and a bodily impairment from database entry 114.A disease may include an abnormal condition of an organism that impairsbodily functions associated with one or more specific symptoms and signsand may include discomfort, distress, dysfunction, injury, a disorder, asyndrome, infection, and/or other atypical variation associated withstructure and/or function of the body. An illness may include any stateof poor health. Some examples of an illness may include cancer, thecommon cold, influenza, pneumonia, and/or high cholesterol. A bodilyimpairment may include a diminished ability in body function and/orstructure. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 6 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 6 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 602. Operation 602 illustratesaccepting an impairment associated with at least one individualincluding at least one of a potential medication reaction or a potentialsusceptibility to a side effect. For example, as shown in FIG. 1,acceptor module 102 may accept an impairment associated with at leastone individual including at least one of a potential medication reactionor a potential susceptibility to a side effect. In one example, acceptormodule 102 can accept from network storage 110 an impairment associatedwith at least one individual including at least one of a potentialmedication reaction or a potential susceptibility to a side effect. Apotential medication reaction may include a possible response a personmay exhibit resulting from at least one drug and/or medicationadministered to the person. A potential medication reaction may includean allergy and/or a drug and/or medication interaction with a separatedrug and/or medication. A potential susceptibility to a side effect mayinclude the probability a certain person may be vulnerable to a sideeffect coupled with a specific drug and/or medication. In someinstances, acceptor module 102 may include a computer processor.

FIG. 7 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 7 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 702, and/or an operation 704.Further, operation 702 illustrates accepting at least one physicaldiagnosis associated with the at least one individual. For example, asshown in FIG. 1, acceptor module 102 may accept at least one physicaldiagnosis associated with the at least one individual. In a specificexample, acceptor module 102 accepts from memory device 112 a physicaldiagnosis associated with a group of ten individuals. A physicaldiagnosis may include identifying a disease and/or condition by itsoutward signs and/or symptoms. Some examples of a physical diagnosis mayinclude identifying influenza and/or identifying Alzheimer's disease. Insome instances, acceptor module 102 may include a computer processor.

Operation 704 illustrates accepting at least one diagnosis of at leastone of a cardiovascular disorder, a digestive disorder, an endocrinedisorder, a hearing disorder, an immune disorder, an inner ear disorder,an integumentary disorder, a lymphatic disorder, a muscular disorder, anervous system disorder, a reproductive disorder, a respiratorydisorder, a skeletal disorder, a visual disorder, or an urinarydisorder. For example, as shown in FIG. 1, acceptor module 102 mayaccept at least one diagnosis of at least one of a cardiovasculardisorder, a digestive disorder, an endocrine disorder, an integumentarydisorder, a lymphatic disorder, a muscular disorder, a nervous systemdisorder, a reproductive disorder, a respiratory disorder, a skeletaldisorder, or an urinary disorder. In a specific instance, acceptormodule 102 can accept from user interface 116 and/or user 118 adiagnosis of a respiratory disorder. A cardiovascular disorder mayinclude a disorder associated with the circulatory system including thepumping and channeling of blood to and from the body and lungs with theheart, the blood, and the blood vessels. Examples of a circulatorydisorder include high blood pressure, coronary heart disease,atherosclerosis, or the like. A digestive disorder may include adisorder associated with the esophagus, the stomach, the liver, thegallbladder, the pancreas, the intestines, the rectum, the anus, and/orthe digestive system including digestion and processing food withsalivary glands. Examples of a digestive disorder include GERD, Crohn'sdisease, IBS, stomach ulcers including those associated with H. pyloriinfection, or the like. An endocrine disorder may include a disorderassociated with the endocrine system including the pancreas, thepituitary gland, the pineal body and/or the pineal gland, the thyroid,the parathyroids, the adrenal glands, and/or communication within thebody using hormones made by the endocrine glands, such as thehypothalamus. Examples of an endocrine disorder include diabetes,acromegaly, or the like. A hearing disorder may include a full orpartial decrease in the ability to detect or understand sounds. Someexamples of a hearing disorder may include otosclerosis, deafness, lossdue to death of auditory hair cells, for example that caused by trauma,and/or unilateral hearing loss. An immune disorder may include adysfunction of the immune system. Examples of an immune disorder mayinclude an immunodeficiency, such as malfunctioning lymphocytes;autoimmunity, such as Coeliac disease and/or autoimmune hepatitis;and/or hypersensitivity, such as asthma. An inner ear disorder mayinclude a balance disorder, such as vertigo, disequilibrium, and/orpre-syncope. An integumentary disorder may include a disorder associatedwith the integumentary system including the skin, hair, and/or nails,such as psoriasis, eczema, dermatitis, or the like. A lymphatic disordermay include a disorder associated with the lymphatic system includingstructures involved in the transfer of lymph between tissues and theblood stream and/or the lymph and the nodes and vessels that transportlymph including the immune system, including defending againstdisease-causing agents with leukocytes, and/or including the tonsils,the adenoids, the thymus, and/or the spleen. Examples of a lymphaticdisorder include lymphedema, lymphadenopathy, or the like. A muscledisorder may include a disorder associated with the muscular systemincluding the structure and/or movement of muscles. Examples of a muscledisorder include muscular dystrophy, myasthenia gravis, an injury, suchas a strain, or the like. A nervous system disorder may include adisorder associated with the nervous system including collecting,transferring, and/or processing information with the brain, the spinalcord, the peripheral nerves, and/or the nerves. Examples of a nervoussystem disorder include multiple sclerosis, fibromyalgia, carpal tunnelsyndrome, or the like. A reproductive disorder may include a disorderassociated with the reproductive system including the sex organs, suchas ovaries, fallopian tubes, the uterus, the vagina, mammary glands,testes, the vas deferens, seminal vesicles, the prostate, and/or thepenis. Examples of a reproductive disorder include erectile dysfunction,endometriosis, fibroids, or the like. A respiratory disorder may includea disorder associated with the respiratory system including the organsused for breathing, the pharynx, the larynx, the trachea, the bronchi,the lungs, and/or the diaphragm. Examples of a respiratory disorderinclude emphysema, asthma, or the like. A skeletal disorder may includea disorder associated with the skeletal system including the structuralsupport and protection with bones, cartilage, ligaments, and/or tendons.Examples of a skeletal disorder include osteoporosis, arthritis,tendonitis, a skeletal injury, such as a bone fracture, or the like. Avisual disorder may include a disease, impairment, and/or lack offunction in the eye and/or in visual perception. Some examples of avisual disorder may include amblyopia, macular degeneration, glaucoma,and/or blindness. A urinary disorder may include a disorder associatedwith the urinary system including the kidneys, the ureters, the bladderand/or urethra involved in fluid balance, electrolyte balance and/or theexcretion of urine. Examples of a urinary disorder include bladderdysfunction, kidney disease, bladder or urethra infection, or the like.In some instances, acceptor module 102 may include a computer processor.

FIG. 8 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 8 illustrates example embodiments where theoperation 210 may include at least one additional operation. Additionaloperations may include an operation 802, an operation 804, an operation806, and/or operation 808.

Operation 802 illustrates accepting at least one of a current treatmentor a proposed treatment associated with the at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept at least oneof a current treatment or a proposed treatment associated with the atleast one individual. In one instance, acceptor module 102 accepts acurrent treatment regime associated with an individual named CathyHansen. A current treatment may include one or a series of treatmentsrecommended, administered, and/or prescribed for a certain individual. Aproposed treatment may include one or a series of treatmentsrecommended, prescribed, and/or not currently administered to a certainindividual. In some instances, acceptor module 102 may include acomputer processor.

Operation 804 illustrates accepting the at least one attribute from amedical history associated with the at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept the at leastone attribute from a medical history associated with the at least oneindividual. In one example, acceptor module 102 may accept from databaseentry 114 an attribute 120 from a medical history including the numberof blood relatives with diabetes associated with an individual namedEmily Smith. A medical history may include a list of previous illnesses,symptoms, medicines, treatments, health risk factors, operations, and/ordoctor visits for an individual and/or a relation of an individual. Insome instances, acceptor module 102 may include a computer processor.

Operation 806 illustrates accepting the at least one attribute from apersonal medical history associated with at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept the at leastone attribute from a personal medical history associated with at leastone individual. In a specific instance, acceptor module 102 can acceptfrom database entry 114 an attribute 120 including, for example, a listof operations from a personal medical history associated with anindividual named Robert Murphy. A personal medical history may include alist of previous illnesses, symptoms, medicines, treatments, health riskfactors, operations, and/or doctor visits associated with at least oneindividual. A personal and/or a family medical history may include lifehistory and/or social history characteristics such as smoking, drinking,drug use, sexual history, exercise history, eating history,nutraceutical history, or the like. In some instances, acceptor module102 may include a computer processor.

Operation 808 illustrates accepting the at least one attribute from afamily medical history associated with the at least one individual. Forexample, as shown in FIG. 1, acceptor module 102 may accept the at leastone attribute from a family medical history associated with the at leastone individual. In one example, acceptor module 102 can accept fromnetwork storage 110 an attribute 120 including a list of family membersthat have had ovarian cancer from a family medical history associatedwith an anonymous individual or an individual named Elizabeth Green. Afamily medical history may include a list of previous illnesses,symptoms, medicines, treatments, health risk factors, operations, and/ordoctor visits associated with family members related to the at least oneindividual. In some instances, acceptor module 102 may include acomputer processor.

FIG. 9 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 9 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 902.

Operation 902 illustrates accepting at least one mental enhancement goalassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one mental enhancementgoal associated with the at least one individual. In one instance,acceptor module 102 can accept a mental enhancement goal associatedwith, for example, an individual named Dorothy Anderson. A mentalenhancement goal may include a mental state and/or situation anindividual may plan to achieve. Some examples of a mental enhancementgoal may include achieving a certain state of mental awareness such asincreased alertness or visual perception, reaching a certain cognitivecapability such as enhanced memory or pattern recognition, maintaining aspecific attention level, and/or reducing or eliminating a phobia. Insome instances, acceptor module 102 may include a computer processor.

FIG. 10 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 10 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1002, an operation 1004, and/or anoperation 1006.

Operation 1002 illustrates accepting at least one mental attributeassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one mental attributeassociated with the at least one individual. In one example, acceptormodule 102 can accept a mental attribute 120 including, for example, anintelligence quotient associated with an individual named Judy Peterson.A mental attribute may include an attribute that may be related toand/or associated with basic mental function and/or high-level brainfunction. Some examples of a mental attribute may include anintelligence quotient (IQ), measurements of brain activity for exampleusing functional MRI or near infra-red technology, and/or measurementsof mental development. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 1004 illustrates accepting at least one mental symptomassociated with the at least one individual. For example, as shown inFIG. 1, acceptor module 102 may accept at least one mental symptomassociated with the at least one individual. In one example, acceptormodule 102 can accept from network storage 110 a mental symptomincluding a stress level measurement associated with an individual namedHeather Swanson. A mental symptom may include a manifestation, sign,and/or an indication of the presence of a disease and/or some othermental disorder and/or abnormality. Some examples of a mental symptommay include lack of attention, indication of stress, hyperactivity,nervousness, and/or lack of responsiveness. In some instances, acceptormodule 102 may include a computer processor.

Operation 1006 illustrates accepting at least one indication of anxiety,an appearance, a behavior, depression, fear, inattention, a mooddisturbance, a phobia, or a psychological test result. For example, asshown in FIG. 1, acceptor module 102 may accept at least one indicationof anxiety, appearance, behavior, depression, fear, inattention, mooddisturbance, phobia, or psychological test result. In one example,acceptor module 102 can accept from user interface 116 and user 118 anindication of anxiety and depression. Anxiety may include feelings offear, apprehension, and/or worry and may be accompanied by physicalsensations. An appearance may include an outward, audible, and/orvisible aspect of a person and/or thing associated with a person. Abehavior may include the manner in which a person and/or thingassociated with a person acts and/or reacts. Depression may include amental state characterized by pessimism, a sense of inadequacy,despondence, despair, a low level of energy, and/or a lack of activity.Fear may be caused by impending danger, perceived evil, and/or pain,whether real or imagined. Inattention may include the failure of aperson to focus attention. A mood disturbance may include a change inemotional state. A phobia may include an irrational, and/or persistentfear of certain situations, objects, activities, and/or people. Apsychological test result may include a sample behavior for inferring acertain generalization about a person. For example, a personality testresult may indicate that person has obsessive/compulsivecharacteristics. In some instances, acceptor module 102 may include acomputer processor.

FIG. 11 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 11 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1102.

Operation 1102 illustrates accepting at least one measurement associatedwith at least one of brain activity, cardiac activity, vascularactivity, peripheral neural signals, hemodynamic activity, or metabolicactivity. For example, as shown in FIG. 1, acceptor module 102 mayaccept at least one measurement associated with at least one of brainactivity, cardiac activity, vascular activity, peripheral neuralsignals, hemodynamic activity, or metabolic activity. In one instance,acceptor module 102 can accept from database entry 114 a measurementassociated with brain activity. Brain activity may include theelectrical activity of the brain, such as that measured by EEG, MEG, orthe like. Other brain activity measurements may include functional MRIimaging, near infra-red imaging, PET scanning, or the like. Cardiacactivity may include electrical activity in the heart, such as thatmeasured by EKG or visual imaging. Vascular activity may include anyactivity and/or function of the circulatory system. Peripheral neuralsignals may include neural signals sent through the peripheral nervoussystem. Hemodynamic activity may include any activity associated withthe circulatory system. Metabolic activity may include any activityassociated with the biochemical reactions occurring in a livingorganism. In some instances, acceptor module 102 may include a computerprocessor.

FIG. 12 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 12 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1202, and/or an operation 1204.

Operation 1202 illustrates accepting at least one mental impairmentassociated with at least one individual. For example, as shown in FIG.1, acceptor module 102 may accept at least one mental impairmentassociated with at least one individual. In one example, acceptor module102 can accept from memory device 112 a mental impairment associatedwith an individual named Richard Lewis. A mental impairment may includea condition or function judged by a health care provider to besignificantly impaired relative to the usual standard of an individualof their group, and may include mental impairment, sensory impairment,and/or mental disease. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 1204 illustrates accepting at least one indication of at leastone of a mood disorder, an anxiety disorder, a psychotic disorder, aneating disorder, a developmental disorder, a phobia, a communicationdisorder, a social disorder, or a personality disorder. For example, asshown in FIG. 1, acceptor module 102 may accept at least one indicationof at least one of a mood disorder, an anxiety disorder, a psychoticdisorder, an eating disorder, a developmental disorder, a phobia, or apersonality disorder. In one instance, acceptor module 102 can acceptfrom user interface 116 and/or user 118 an indication of a mood disorderincluding a mood change and the onset of depression in a specificindividual. A mood disorder may include a condition whereby theprevailing emotional mood is distorted or inappropriate to thecircumstances, and may include examples such as bipolar disorder, analteration in mood, and/or depression. An anxiety disorder may includenervous system disorders such as irrationality, illogical worry notbased on fact, fear, and/or phobia. A psychotic disorder may include astate of mind in which thinking becomes irrational and/or disturbed andmay include hallucinations, abnormal perception, mania, dementia,delusions and/or delusional beliefs, delirium, depression, psychosispersonality disorder, personality changes, and/or disorganized thinking.An eating disorder may include a compulsion to eat and/or avoid eatingthat negatively affects physical and/or mental health. Some examples ofan eating disorder may include anorexia nervosa and bulimia nervosa. Adevelopmental disorder may include a disorder occurring in a child'sdevelopment, which may retard development. Some examples of adevelopmental disorder may include an emotional disorder, a cognitivedisorder, and/or a mental disorder accompanied by physical traits, suchas Down syndrome. A phobia may include an irrational, intense, and/orpersistent fear of certain situations, objects, activities, and/orpersons. Examples of phobias include social phobias, arachnophobia,xenophobia, and/or claustrophobia. A communication disorder may includea disease and/or a condition partially or totally preventing humancommunication. Some examples of a communication disorder may includeautism, stuttering, and/or aphasia. A social disorder may include acondition characterized by a difficulty in human interaction and/oremotional discomfort in social situations. Some examples of a socialdisorder may include stage fright, social anxiety disorder, and/orshyness. A personality disorder may include a disorder characterized bypathological trends in personality structure. Some examples of apersonality disorder may include a paranoid personality disorder, anarcissistic personality disorder, and/or an obsessive-compulsivepersonality disorder. In some instances, acceptor module 102 may includea computer processor.

FIG. 13 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 13 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1302, and/or an operation 1304.Further, operation 1302 illustrates accepting at least one mentaldiagnosis associated with at least one individual. For example, as shownin FIG. 1, acceptor module 102 may accept at least one mental diagnosisassociated with at least one individual. In a specific instance,acceptor module 102 accepts from memory device 112 a mental diagnosisincluding a phobia associated with an anonymous individual or anindividual named Roy Black. A mental diagnosis may include identifying amental disorder and/or condition by its symptoms. Some examples of amental diagnosis may include a mood disorder such as depression, ananxiety disorder such as PTSD, a behavioral disorder such as ADHD, apersonality disorder such as borderline personality disorder, and/or aphobia. Mental disorders may include those listed in the Diagnostic andStatistical Manual of Mental Disorders (DSM). In some instances,acceptor module 102 may include a computer processor.

Operation 1304 illustrates accepting at least one of a depression, aphobia, an anxiety disorder, a personality disorder, a psychoticdisorder, a developmental disorder, a panic disorder, a bipolardisorder, schizophrenia, an eating disorder, obsessive compulsivedisorder, post traumatic stress disorder, an attentional disorder, acommunication disorder, a social disorder, or a mood disorder. Forexample, as shown in FIG. 1, acceptor module 102 may accept at least oneof a depression, a phobia, an anxiety disorder, a personality disorder,a psychotic disorder, a developmental disorder, a panic disorder, or amood disorder. In one example, acceptor module 102 accepts from databaseentry 114 a diagnosis of depression. Depression may include a mentalstate characterized by a pessimistic sense of inadequacy and/or adespondent lack of activity. A phobia may include an irrational,intense, and/or persistent fear of certain situations, objects,activities, and/or persons. Some phobias may include social phobias,arachnophobia, xenophobia, and/or claustrophobia. An anxiety disordermay include nervous system disorders such as irrationality, illogicalworry not based on fact, fears, and/or phobias. A personality disordermay include a disorder characterized by pathological trends inpersonality structure. Some examples of a personality disorder mayinclude a paranoid personality disorder, a narcissistic personalitydisorder, and/or an obsessive-compulsive personality disorder. Apsychotic disorder may include a state of mind in which thinking becomesirrational and/or disturbed and may include hallucinations, delusionalbeliefs, personality changes, and/or disorganized thinking. Adevelopmental disorder may include a disorder occurring in a child'sdevelopment, which may often retard development. Some examples of adevelopmental disorder may include psychological or physical disorders.A panic disorder may include a condition characterized by recurringpanic attacks in combination with significant behavioral change. Abipolar disorder may include a mood disorder characterized by thepresence of one or more episodes of abnormally elevated mood, such asBipolar I disorder, Bipolar II disorder, cyclothymia, and/orBipolar-NOS. Schizophrenia may include a mental illness characterized byimpairments in the perception or expression of reality, most commonlymanifesting as auditory hallucinations, paranoid or bizarre delusions ordisorganized speech and thinking in the context of significant social oroccupational dysfunction. An eating disorder may include a compulsion toeat or avoid eating, such as anorexia nervosa and/or bulimia nervosa.Obsessive compulsive disorder may include a psychiatric anxiety disordercharacterized by obsessive, distressing, intrusive thoughts and relatedcompulsions which attempt to neutralize the obsessions. Post traumaticstress disorder may include an anxiety disorder that can develop afterexposure to one or more terrifying events in which grave physical harmoccurred or was threatened. An attentional disorder may include apersistent pattern of inattention and/or hyperactivity, as well asforgetfulness, poor impulse control or impulsivity, and distractibility,such as attention-deficit hyperactivity disorder(ADHD). A communicationdisorder may include a disease and/or a condition partially or totallypreventing human communication. Some examples of a communicationdisorder may include autism, stuttering, and/or aphasia. A socialdisorder may include a condition characterized by a difficulty in humaninteraction and/or emotional discomfort in social situations. Someexamples of a social disorder may include stage fright, social anxietydisorder, and/or shyness. A mood disorder may include a conditionwhereby the prevailing emotional mood is distorted or inappropriate tothe circumstances and may include examples such as bipolar disorderand/or depression. In some instances, acceptor module 102 may include acomputer processor.

FIG. 14 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 14 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1402. Further, operation 1402illustrates accepting at least one past mental therapy associated withthe at least one individual. For example, as shown in FIG. 1, acceptormodule 102 may accept at least one past mental therapy associated withthe at least one individual. In one instance, acceptor module 102 canaccept from database entry 114 a past mental therapy associated with anindividual named James Williams or an anonymous individual. A pastmental therapy may include a list and/or a record of at least one mentaltherapy, such as an anti-depressant medication, administered to at leastone individual. In some instances, acceptor module 102 may include acomputer processor.

FIG. 15 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 15 illustrates example embodiments whereoperation 210 may include at least one additional operation. Additionaloperations may include an operation 1502, an operation 1504, and/or anoperation 1506.

Operation 1502 illustrates accepting the at least one attributeassociated with the at least one individual from a health care provider.For example, as shown in FIG. 1, acceptor module 102 may accept the atleast one attribute associated with the at least one individual from ahealth care provider. In one example, acceptor module 102 can acceptfrom user interface 116 and/or user 118 an attribute 120 including amedication history associated with a group of fifty individuals from ahealth care provider 136. A health care provider may include a hospital,a doctor, a nurse, a medical clinic, a dentist, and/or any provider ofpreventive, diagnostic, therapeutic, rehabilitative, maintenance, orpalliative care and/or counseling. A healthcare provider may include aseller and/or dispenser of prescription drugs or medical devices. Insome instances, acceptor module 102 may include a computer processor.

Operation 1504 illustrates accepting the at least one attributeassociated with the at least one individual from a licensed health careprovider. For example, as shown in FIG. 1, acceptor module 102 mayaccept the at least one attribute associated with the at least oneindividual from a licensed health care provider. In one instance,acceptor module 102 accepts from memory device 112 an attribute 120including a symptom indication a phobia associated with an individualnamed Robert Clark from a licensed health care provider 136. A licensedhealth care provider may include a person licensed by a governingauthority, such as a state, to provide medical and/or health care. Someexamples of a licensed health care provider may include a licensedmedical doctor or physician, a licensed physician's assistant, and/or alicensed nurse practitioner. In some instances, acceptor module 102 mayinclude a computer processor.

Operation 1506 illustrates accepting the at least one attributeassociated with the at least one individual from an alternative medicineprovider. For example, as shown in FIG. 1, acceptor module 102 mayaccept the at least one attribute associated with the at least oneindividual from an alternative medicine provider. In one instance,acceptor module 102 can accept from network storage 110 an attribute 120associated with an individual named Connie Martin from an alternativemedicine provider. An alternative medicine provider may include aprovider of folk medicine, herbal medicine, diet fads, homeopathy, faithhealing, new age healing, chiropractic, acupuncture, aromatherapy,naturopathy, massage, reflexology, hypnotism, and/or music therapy. Insome instances, acceptor module 102 may include a computer processor.

FIG. 16 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 16 illustrates example embodiments whereoperation 220 may include at least one additional operation. Additionaloperations may include an operation 1602.

Operation 1602 illustrates searching at least one prescriptionmedication database and at least one artificial sensory experiencedatabase. For example, as shown in FIG. 1, querier module 104 may searchat least one prescription medication database and at least oneartificial sensory experience database. In one example, querier module104 searches a medication database 124 and an artificial sensoryexperience database 126. A database may include a collection of dataorganized for convenient access. The database may include informationdigitally stored in a memory device 112, as at least a portion of atleast one database entry 114, and/or in network storage 110. In someinstances, the database may include information stored non-digitallysuch as at least a portion of a book, a paper file, and/or anon-computerized index and/or catalog. Non-computerized information maybe received by acceptor module 102 by scanning or by manually enteringthe information into a digital format. A prescription database and/ormedication database may include any database associated with at leastone prescription medication and may be available to health careprofessionals and/or the public. An artificial sensory experiencedatabase may include any database associated with at least oneartificial sensory experience and may include a database accessible bythe public and/or a health care provider. In some instances, acceptormodule 102 and/or querier module 104 may include one or more computerprocessors.

FIG. 17 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 17 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 1702, and/or an operation 1704.

Operation 1702 illustrates selecting the at least one prescriptionmedication from a physician's desk reference database. For example, asshown in FIG. 1, selector module 106 may select the at least oneprescription medication from a physician's desk reference database. Inone example, selector module 106 selects the at least one prescriptionmedication from a physician's desk reference database 122, such as a PDRpsychiatry database. In some instances, selector module 106 may includea computer processor.

Operation 1704 illustrates selecting at least one of an analgesic, anantacid, an antiarrhythmic, an antibacterial, an antibiotic, ananticoagulant, a thrombolytic, an anticonvulsant, an antidiarrheal, anantiemetic, an antifungal, an anti-allergic agent, an antihistamine, anantihypertensive, an anti-anginal, an anti-asthmatic, ananti-inflammatory, an antineoplastic, an antipyretic, an antiviral, ananti-ulcer agent, an antidyspeptic, an antacid, a beta-blocker, abronchodilator, a cold treatment, a corticosteroid, an antitussive, acytotoxic agent, a decongestant, a diuretic, an expectorant, a hormone,a hypoglycemic, an immunosuppressive, a laxative, a muscle relaxant, asedative, a female sex hormone, a mate sex hormone, a tranquilizer, anappetite modulator, or a vitamin. For example, as shown in FIG. 1,selector module 106 may select at least one of an analgesic, an antacid,an antiarrhythmic, an antibacterial, an antibiotic, an anticoagulant, athrombolytic, an anticonvulsant, an antidiarrheal, an antiemetic, anantifungal, an anti-allergic agent, an antihistamine, anantihypertensive, an anti-anginal, an anti-asthmatic, ananti-inflammatory, an antineoplastic, an antipyretic, an antiviral, ananti-ulcer agent, an antidyspeptic, an antacid, a beta-blocker, abronchodilator, a cold treatment, a corticosteroid, a cough suppressant,an antitussive, a cytotoxic agent, a decongestant, a diuretic, anexpectorant, a hormone, a hypoglycemic, an immunosuppressive, alaxative, a muscle relaxant, a sedative, a female sex hormone, a malesex hormone, a tranquilizer, an appetite modulator, or a vitamin. Ananalgesic may include a drug and/or other medication suitable forrelieving pain. Additionally, an analgesic may be effective forrelieving different degrees of pain. Some examples of an analgesic mayinclude narcotics such as morphine or oxycodone, non-narcotics, an NSAIDsuch as aspirin or naproxen or ibuprofen, and/or acetaminophen. Anantacid may include a substance for neutralizing stomach acid, such as aproton pump inhibitor. Some examples of an antacid may includeimeprazole and/or a pharmaceutical composition containing aluminumhydroxide, magnesium hydroxide, aluminum carbonate, calcium carbonate,sodium bicarbonate, hydrotalcite, bismuth subsalicylate, magaldrate,and/or simethicone.

An antiarrhythmic may include a drug for controlling a heartbeatirregularity. Some examples of an antiarrhythmic may include a betablocker such as propanolol, and/or lidocaine, verapamil, and/orquinidine. An antibacterial may include a drug used to treat aninfection. Some examples of an antibacterial may include amoxicillinand/or ciprofloxacin. An antibiotic may include a drug made fromnaturally occurring and/or synthetic substances for combating abacterial infection. Some examples of an antibiotic may includepenicillin, streptomycin, and/or sulfonamide-based drugs. Ananticoagulant may include an agent for preventing blood clots. Anexample of an anticoagulant may include a vitamin K antagonist, such aswarfarin, and/or aspirin. A thrombolytic may help dissolve and dispersea blood clot and may be prescribed for patients with recent arterial orvenous thrombosis. A thrombolytic may be derived from Streptomyces spp.and/or recombinant DNA technology and may include streptokinase,urokinase, and/or a tissue plasminogen activator (TPA) such asalteplase.

An anticonvulsant may include a pharmaceutical administered for theprevention of seizures. Some examples of an anticonvulsant may include abarbiturate, a carbamate, a fatty acid derivative, and/or a sulfonamide.An antidiarrheal may include a drug utilized for the relief of diarrhea.Some examples of an antidiarrheal may include an antispasmodic such asdiphenoxylate and loperamide, a bismuth compound, a bulking agent,and/or an absorbent. An antiemetic may include a drug used to treatnausea and vomiting. Some examples of an antiemetic may include a 5-HT3receptor antagonist, a dopamine antagonist, and/or a histamine. Anantifungal may include a drug used to treat fungal infections, the mostcommon of which affect the hair, skin, nails, and/or mucous membranes.Some examples of antifungals may include polyene antifungals, imidazoleand triazole antifungals, and/or allylamines. An anti-allergenic agentmay include an agent characterized by preventing and/or reducing theeffect of an allergen. Some examples of an anti-allergenic may includean antihistamine, cortisone, hydrocortisone, and/or epinephrine. Anantihistamine may include an agent used for counteracting the effects ofhistamine. Some examples of an antihistamine may include a H1-receptorantagonist and/or a H2-receptor antagonist. An antihypertensive mayinclude drugs utilized for lowering blood pressure. Some examples of anantihypertensive may include a diuretic, an adrenergic receptorantagonist, and/or an ACE inhibitor. An anti-anginal may include anagent used for preventing and/or reducing angina and/or chest pain. Someexamples of an anti-anginal may include aspirin, ranolazine, and/orivabradine. An anti-asthmatic may include an agent for preventing and/orreducing asthma and/or its effects. Some examples of an anti-asthmaticmay include albuterol, an inhaled steroid, for example budesonide orfluticasone, and/or ipratropium bromide.

An anti-inflammatory may include an agent utilized to reduceinflammation and/or to treat redness, heat, swelling, and/or increasedblood flow associated for example, that seen with an infection orinjury, or in many chronic diseases such as rheumatoid arthritis andgout. Some anti-inflammatories may include steroids, and/or NSAIDs suchas naproxen, ibuprofen, and/or aspirin. An antineoplastic may includedrugs used to treat cancer and to inhibit and/or prevent the developmentof tumors. Some antineoplastics may include alkylating agents,antimetabolites, enzymes, enzyme inhibitors, immune modulators, andtaxoids. An antipyretic may include a drug used to reduce a fever. Someexamples of an antipyretic may include aspirin and/or acetaminophen. Anantiviral may include a drug used to treat viral infections and/or toprovide temporary protection against viral infections such as influenza.Some examples of an antiviral may include an interferon, acyclovir,ribavirin, and/or oseltamivir. An anti-ulcer agent may include an agentused for preventing and/or lessening the effect of an ulcer, includingstomach ulcers, mouth ulcers, or other types of ulcers. Some examples ofan anti-ulcer agent may include a bismuth compound, a prostaglandinanalogue, and/or cimetidine. An antidyspeptic may include an agent usedfor treating and/or preventing dyspepsia. Some examples of anantidyspeptic may include simethicone and/or a proton pump inhibitor,such as esomeprazole. An antacid may include a substance, often a base,which may counteract stomach acidity. Some examples of an antacid mayinclude magnesium hydroxide, aluminum hydroxide, calcium carbonate,and/or bismuth subsalicylate. A beta-blocker may include abeta-adrenergic blocking agent utilized for reducing the oxygen needs ofthe heart by reducing the heartbeat rate. Some examples of abeta-blocker may include propranolol, esmolol, bisoprolol, and/ortimolol. A bronchodilator may include an agent utilized for opening thebronchial tubes within the lungs when the tubes have become narrowed,for example, by muscle spasm and may be used for treating asthma. Someexamples of a bronchodilator may include albuterol and/or ipratropiumbromide. A cold treatment may include an agent utilized for treatingaches, pains, and/or fever accompanying a cold. Some cold treatments mayinclude aspirin, acetaminophen, a decongestant, an antihistamine, and/orcaffeine.

A corticosteroid may include a hormonal preparation used as ananti-inflammatory for arthritis or asthma and/or treating somemalignancies or compensating for a deficiency of natural hormones. Someexamples of a corticosteroid may include cortisol and/or aldosterone. Acough suppressant may include an agent used to soothe irritation causedby coughing and/or to prevent coughing. Some examples of a coughsuppressant may include codeine, an antihistamine, and/ordextromethorphan. An antitussive may include a cough suppressant. Acytotoxic agent may include a drug used for killing and/or damagingcells. Some examples of a cytotoxic agent may include actinomycin-D,azathioprine, bleomycin, melphalan, busulphan, doxorubicin, etoposide,an antineoplastic agent, and/or an apoptotic agent. A decongestant mayinclude an agent for reducing the swelling of the mucous membraneslining the nose and/or throat. Some examples of a decongestant mayinclude pseudoephedrine and phenylephrine. A diuretic may include anagent for increasing the quantity of urine produced by the kidneys andpassed out of the body. Some examples of a diuretic may includehydrochlorothiazide, spironolactone, mannitol, and/or glucose. Anexpectorant may include an agent for stimulating the flow of saliva,loosening and thinning mucus in airways, and/or promoting a moreproductive cough as to eliminate phlegm from the respiratory tract. Anexample of an expectorant may include guaifenesin. A hormone may includemolecules produced naturally by the endocrine glands. Some examples of ahormone may include steroid hormones, amine-derived hormones, peptidehormones, and/or lipid and phospholipid-derived hormones. A hypoglycemicmay include an agent for lowering the level of glucose in the blood.Some examples of a hypoglycemic may include a sulfonylurea, ameglitinide, a biguanide, a thiazolidinedione, and/or aalpha-glucosidase inhibitor. An immunosuppressive may include an agentfor preventing or reducing the body's normal reaction to invasion bydisease and/or foreign tissues. Some examples of an immunosuppressivemay include a drug such as a corticosteroid, cyclosporine, rapamycin,which acts on immunophilins, and/or an antibody.

A laxative may include an agent for increasing the frequency and ease ofbowel movements. Some examples of a laxative may includemethylcellulose, docusate, mineral oil, and/or magnesium hydroxide. Amuscle relaxant may include an agent utilized for relieving musclespasms. Some examples of a muscle relaxant may include neuromuscularblocking drugs, carisoprodol, cyclobenzaprine, metaxalone, abenzodiazepine and/or a tranquilizer. A sedative may include a substancewhich depresses the central nervous system and may result in calmness,relaxation, reduction of anxiety, sleepiness, and/or slowed breathing.Some examples of a sedative may include zolpidem, and/or eszopiclone. Afemale sex hormone may include a hormone responsible for the developmentof female secondary sexual characteristics. Some examples of a femalesex hormone may include estrogen and progesterone. A male sex hormonemay include a hormone responsible for the development of secondary malesexual characteristics. One example of a male sex hormone may includetestosterone. Sex hormone-related agents may include agentsmetabolically related to sex hormones. Examples of sex hormone-relatedagents may include sterols, androgens (testosterone ), progestogensestrogens (estradiols, estrone), follicle-stimulating hormone,luteinizing hormone, inhibin B, anti-Mullerian hormone thyroid-relatedhormones. A tranquilizer may include any drug having a calming and/orsedative effect. Some examples of a tranquilizer may include anantidepressant, a barbiturate, and/or a benzodiazepine. An appetitemodulator may include an agent used for regulating and/or adjustingappetite. Some examples of an appetite modulator may include recombinantPYY 3-36 and/or sibutramine. A vitamin may include chemicals essentialin relatively small quantities for good health. Some examples of avitamin may include Vitamin A, Vitamin C, Vitamin D, and/or Vitamin K.

In one instance, selector module 106 can select an analgesic and anantipsychotic for subsequent presentation, perhaps in response toaccepting a pain symptom and a hallucination symptom as the at least oneattribute. In some instances, selector module 106 may include a computerprocessor.

FIG. 18 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 18 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 1802. Further, operation 1802illustrates selecting at least one of an antiparalytic, an antimanic, anantineuratgic, an anti-dyskinesia agent, an antispasmodic, anantiadrenergic, an antimuscarinic, a neuromimetic agent, a neuromuscularagent, an antianxiety agent, an antipsychotic, an antidepressant, a moodstabilizer, a stimulant, an anxiolytic, a hypnotic, or a sleeping agent.For example, as shown in FIG. 1, selector module 106 may select at leastone of an antiparalytic, an antimanic, an antineuralgic, ananti-dyskinesia agent, an antispasmodic, an antiadrenergic, anantimuscarinic, a neuromimetic agent, a neuromuscular agent, anantianxiety drug, an antipsychotic, an antidepressant, a moodstabilizer, a stimulant, an anxiolytic, a hypnotic, and/or a sleepingagent such as a long-acting barbiturate. In one example, selector module106 selects an antianxiety drug and a sleeping agent. An antiparalyticmay include an agent used for preventing the toss of and/or recoveringmuscle function. One example of an antiparalytic may includemethylprednisolone. An antimanic may include an agent used for treatingand/or suppressing mania. Some examples may include lamotrigine and/orcarbamazepine. An antineuralgic may include an agent for relievingparoxysmal nerve pain. One example of an antineuralgic may includecarbamazepine. An anti-dyskinesia agent may include an agent used forreducing and/or preventing dyskinesia, including involuntary musclemovement. One example of an anti-dyskinesia agent may includemethylenedioxymethamphetamine. An antispasmodic may include a drug or anherb that suppresses smooth muscle contraction. Some examples of anantispasmodic may include dicyclomine and/or hyoscyamine. Anantiadrenergic may include a medication for inhibiting the functioningof the sympathetic nervous system. Some examples of an antiadrenergicmay include clonidine and/or mecamylamine. An antimuscarinic may includean agent for reducing the activity of the muscarinic acetylcholinereceptor. Some examples of an antimuscarinic may include atropine and/orhyoscine. A neuromimetic agent may include an agent that mimics theresponse of an effector organ to nerve impulses. A neuromuscular agentmay block neuromuscular transmission at the neuromuscular junction andcause paralysis of the affected skeletal muscles. Some examples of aneuromuscular agent may include atracurium and/or vecuronium. Anantianxiety drug may include a drug for suppressing anxiety and relaxingthe muscles. An antianxiety drug may include a sedative, a tranquilizer,an anxiolytic, such as a benzodiazepine, alprazolam and/or diazepam, anantidepressant, a short-acting barbiturate, and/or an herbal treatment,such as chamomile, kava extract, Kratom, and/or valerian. Anantipsychotic may include a group of drugs commonly used to treatpsychosis and may include phenothiazines, thioxanthenes, butyrophenones,risperidone, amisulpride, and/or other suitable drugs. An antidepressantmay include a psychiatric medication or other substance, such as anutrient or herb, used for alleviating depression or dysthymia. Someexamples of an antidepressant may include a selective serotonin reuptakeinhibitor, such as Prozac and/or Zoloft, and/or aserotonin-norepinephrine reuptake inhibitor, such as Cymbalta. A moodstabilizer may include a psychiatric medication used to treat mooddisorders characterized by intense and sustained mood shifts. Someexamples of a mood stabilizer may include lithium carbonate and/orlamotrigine. A stimulant may include substances that may temporarilyincrease alertness and awareness, such as caffeine, ephedrine, and/ornicotine. An anxiolytic may include a substance used for the treatmentof anxiety, such as a benzodiazepine and/or a barbiturate. A hypnoticmay include substances that induce sleep, such as a barbiturate and/oran antihistamine (diphenhydramine). A sleeping agent may include anynumber of medications for helping a person sleep and/or stay asleep andmay include benzodiazepines, antidepressants, melatonin, and/orantihistamines as well as other suitable substances. In some instances,selector module 106 may include a computer processor.

FIG. 19 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 19 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 1902, an operation 1904, and/or anoperation 1906.

Operation 1902 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a behavior, asymptom, or a diagnosis. For example, as shown in FIG. 1, selectormodule 106 may select the at least one prescription medication at leastpartially based on at least one of a behavior, a symptom, or adiagnosis. In one instance, selector module 106 can select aprescription medication based on a diagnosis. A behavior may include themanner a person behaves toward other people and/or a certaincircumstance. A symptom may include a subjective indicator of a healthproblem reported by an individual, or a sign of a health problem noticedby another, perhaps a doctor. A symptom may be evidence of a disease, adisability, an impairment, and/or a condition. A diagnosis may includean identification of a disease, a disability, an impairment, and/or acondition. In some instances, selector module 106 may include a computerprocessor.

Operation 1904 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a susceptibilityto a drug side effect or a drug interaction. For example, as shown inFIG. 1, selector module 106 may select the at least one prescriptionmedication at least partially based on at least one of a susceptibilityto a drug side effect or a drug interaction. In one instance, selectormodule 106 can select a prescription medication based on asusceptibility to a drug side effect including an allergy. Asusceptibility to a drug side effect may include a probability a certainperson may be vulnerable to a side effect associated with a specificdrug and/or medication. A susceptibility to a drug side effect mayinclude predisposition to a particular drug side effect or class of drugside effects, such as upset stomach associated with aspirinformulations. A drug reaction may include a possible response a personmay exhibit resulting from at least one drug and/or medicationadministered to the person. A drug reaction may include an allergyand/or a drug and/or medication interaction with a separate drug and/ormedication. In some instances, selector module 106 may include acomputer processor.

Operation 1906 illustrates selecting a prescription medication and atleast one alternative medicine treatment as the at least oneprescription medication. For example, as shown in FIG. 1, selectormodule 106 may select a prescription medication and at least onealternative medicine treatment as the at least one prescriptionmedication. In one instance, selector module 106 can select aprescription medication and at least one alternative medicine treatmentas the at least one prescription medication. A prescription medicationmay include a medication, drug, and/or treatment available only withwritten instructions from a doctor, dentist, and/or other licensedprofessional. An alternative medicine treatment may include medicaland/or nutraceutical treatments and/or practices utilized instead ofstandard medical treatments. Some examples of alternative medicinetreatments may include chiropractic, herbal medicine, acupuncture,homeopathy, naturopathy, and/or spiritual devotions. In some instances,selector module 106 may include a computer processor.

FIG. 20 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 20 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2002, and/or an operation 2004.

Operation 2002 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a medicationhistory of the at least one individual or an artificial sensoryexperience history of the at least one individual. For example, as shownin FIG. 1, selector module 106 may select the at least one prescriptionmedication at least partially based on at least one of a medicationhistory of the at least one individual or an artificial sensoryexperience history of the at least one individual. In one example,selector module 106 can select a prescription medication based on amedication history of an individual named Jennifer Harris or ananonymous individual. A medication history may include any record ofadministered medications and/or drugs that may exist for an individual.An artificial sensory experience history may include any record of anartificial sensory experience associated with an individual. In someinstances, selector module 106 may include a computer processor.

Operation 2004 illustrates selecting the at least one prescriptionmedication at least partially based on at least one of a genetic or anepigenetic profile. For example, as shown in FIG. 1, selector module 106may select the at least one prescription medication at least partiallybased on at least one of a genetic or an epigenetic profile. In oneinstance, selector module 106 can select a prescription medication basedon a genetic profile. A genetic profile may include hereditaryinformation encoded in the genetic sequence of an individual. Anepigenetic profile may include information regarding chromatin and/orDNA modifications that are stable over rounds of cell division but donot involve changes in the underlying DNA sequence of the organism, suchas histone acetylation and/or DNA methylation. Other epigeneticinformation may be found in higher-order chromatin structure. In someinstances, selector module 106 may include a computer processor.

FIG. 21 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 21 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2102, and/or an operation 2104.

Operation 2102 illustrates selecting at least one virtual experience asthe at least one artificial sensory experience. For example, as shown inFIG. 1, selector module 106 may select at least one virtual experienceas the at least one artificial sensory experience. In one example,selector module 106 can select a virtual experience as the artificialsensory experience. A virtual experience may include an experience witha computer-simulated environment. Such a virtual experience may beinteractive or non-interactive. Some examples of a virtual experiencemay include an experience with a virtual world, a simulated reality, acomputer game, and/or a virtual tour, and may involve input devices suchas a keyboard, a mouse, an accelerometer-containing input device, and/ora wired glove. A virtual experience may also involve a visual and/orauditory monitoring device such as a video monitor, goggles,loudspeakers, or the like. Examples of a virtual experience includesecond life, snow world, or the like. In some instances, selector module106 may include a computer processor.

Operation 2104 illustrates selecting at least one of a virtual world, asocial networking website, an online game, an online educationalexperience, a networked game, or a single-player game. For example, asshown in FIG. 1, selector module 106 may select at least one of avirtual world, a social networking website, an online game, an onlineeducational experience, a networked game, or a single-player game. Inone instance, selector module 106 can select a virtual world. A virtualworld may include a computer-based simulated environment intended forits users to inhabit and interact via avatars, such as second life. Asocial networking website may include a website for observing and/orinteracting with one or more personal and/or professional relationshipsbetween individuals. Some examples of a social networking website mayinclude MySpace, GeoCities, Facebook, and/or LinkedIn. In one instance,selector module 106 may select Facebook as the social networking websiteand may include directions to Facebook to implement a color schemeincluding bright colors, such as yellow and light blue, for preventingthe onset of depression in a depression prone viewer. An online game mayinclude a game played over a network, such as hardwired terminals, awireless network, a modem network, a video console, and/or the internet.Some online games may include virtual worlds and/or virtual communities.Examples of online games may include World of Warcraft (WoW), FinalFantasy XI, Lineage II, Guild Wars, and/or RuneScape. An onlineeducational experience may include a tutorial, a lesson, and/or anonline class. Some examples of an online educational experience mayinclude a HTML tutorial, an online piano lesson, and/or an online degreeprogram from the University of Phoenix. A networked game may include anygame played by more than one player and may be played on a computer. Anexample of a networked game may include World of Warcraft (WoW). Asingle-player game may include any game that can be played by one playerand that may or may not be played on a computer. Examples of asingle-player game includes solitaire, puzzle games such as Tetris, Callof Duty, and Guitar Hero. In some instances, selector module 106 mayinclude a computer processor.

FIG. 22 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 22 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2202, and/or an operation 2204.

Operation 2202 illustrates selecting at least one real-world sensorystimulus as the at least one artificial sensory experience. For example,as shown in FIG. 1, selector module 106 may select at least onereal-world sensory stimulus as the at least one artificial sensoryexperience. In one instance, selector module 106 can select a real-worldsensory stimulus including an aroma as an artificial sensory experience.Some examples of a real-world sensory stimulus may include aromas and/orsmells, sounds, sights, touch, pressure, temperature and/or heat, and/orvibration. In some instances, selector module 106 may include a computerprocessor. Further, operation 2204 illustrates selecting at least one ofa smell, a taste, a sound, a physical contact, or a sight as the atleast one real-world sensory stimulus. For example, as shown in FIG. 1,selector module 106 may select at least one of a smell, a taste, asound, a physical contact, or a sight as the at least one real-worldsensory stimulus. In one example, selector module 106 selects a smelland a taste as a real-world sensory stimulus. A smell may include anyproperty detected by the nose and/or olfactory system. A taste mayinclude any flavor and/or property detected by the tongue and/or tastebuds. A sound may include any sound wave that may be detected by theeardrum. A physical contact may include anything related to touch, feel,and/or detection by the skin and/or body, and/or physical activityincluding exercise. In one instance, selector module 106 may select aphysical contact including physical exercise associated withparticipating in playing a tennis game on a Nintendo Wii video gameconsole, for example. A sight may include any image, and/or lightdetected by the eyes. In some instances, selector module 106 may includea computer processor.

FIG. 23 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 23 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2302, an operation 2304, and/or anoperation 2306.

Operation 2302 illustrates selecting the at least one artificial sensoryexperience at least partially based on at least one of a behavior, asymptom, or a diagnosis. For example, as shown in FIG. 1, selectormodule 106 may select the at least one artificial sensory experience atleast partially based on at least one of a behavior, a symptom, or adiagnosis. In one example, selector module 106 can select an artificialsensory experience based on behavior entered by a user 118 via a userinterface 116. A behavior may include the manner in which a personand/or thing acts and/or reacts. A symptom may include a manifestation,sign, and/or an indication of the presence of a disease and/or someother disorder and/or abnormality. A diagnosis may include identifying adisease and/or condition by its signs and/or symptoms. For example,selector module 106 and/or system 100 may select an immersive virtualreality experience as the at least one artificial sensory experience atleast partially based on a pain symptom and/or a third-degree burndiagnosis. In some instances, selector module 106 may include a computerprocessor.

Operation 2304 illustrates selecting the at least one artificial sensoryexperience at least partially based on at least one demographiccharacteristic of the at least one individual. For example, as shown inFIG. 1, selector module 106 may select the at least one artificialsensory experience at least partially based on at least one demographiccharacteristic of the at least one individual. In one example, selectormodule 106 can select an artificial sensory experience based on ademographic characteristic the at least one individual. A demographiccharacteristic may include a socioeconomic, age, gender, and/or othersimilar factor defining a certain population. For example, selectormodule 106 and/or system 100 may select a virtual reality experiencesuch as a Sesame Street or Disney-themed experience as the at least oneartificial sensory experience at least partially based on an indicationthat the individual is aged 6-10 years old. In some instances, selectormodule 106 may include a computer processor.

Further, operation 2306 illustrates selecting the at least oneartificial sensory experience at least partially based on at least oneof geographic location, family status, age, gender, weight, ethnicity,body mass index, household size, or income of the at least oneindividual. For example, as shown in FIG. 1, selector module 106 mayselect the at least one artificial sensory experience at least partiallybased on at least one of geographic location, family status, age,gender, weight, ethnicity, body mass index, household size, or income ofthe at least one individual. In one example, selector module 106 canselect the artificial sensory experience based on an age and a weightassociated with the at least one individual. A geographic location mayinclude a location where an individual currently resides, has resided inthe past, and/or has visited. A family status may include maritalstatus, status and/or presence of children, and/or the status and/orhealth of extended family. In some instances, selector module 106 mayinclude a computer processor.

FIG. 24 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 24 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2402, and/or an operation 2404.

Operation 2402 illustrates selecting the at least one artificial sensoryexperience at least partially based on at least one of a medicationhistory or an artificial sensory experience history of the at least oneindividual. For example, as shown in FIG. 1, selector module 106 mayselect the at least one artificial sensory experience at least partiallybased on at least one of a medication history or an artificial sensoryexperience history of the at least one individual. In one instance,selector module 106 can select an artificial sensory experience based onan artificial sensory experience history of the at least one individual.An artificial sensory experience history may include any record of atleast one administered artificial sensory experience history. Forexample, system 100 and/or selector module 106 may select a modifiedfacebook webpage having a cheerful color scheme at least partly based ona facebook usage history for an individual with signs of depression. Insome instances, selector module 106 may include a computer processor.

Operation 2404 illustrates selecting a preferred artificial sensoryexperience and at least one alternative artificial sensory experience.For example, as shown in FIG. 1, selector module 106 may select apreferred artificial sensory experience and at least one alternativeartificial sensory experience. In one example, selector module 106 canselect a preferred artificial sensory experience and at least onealternative artificial sensory experience. A preferred artificialsensory experience may include a more desirable artificial sensoryexperience due to a lack of and/or a reduced level of side effects,reduced impact upon the individual, and/or increased compatibility withanother medications and/or treatment. An alternative artificial sensoryexperience may include any artificial sensory experience in addition tothe preferred artificial sensory experience and may be less desirablethan the preferred artificial sensory experience due to side effectsand/or increased impact upon the individual. In some instances, selectormodule 106 may include a computer processor.

FIG. 25 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 25 illustrates example embodiments whereoperation 230 may include at least one additional operation. Additionaloperations may include an operation 2502, an operation 2504, and/or anoperation 2506.

Operation 2502 illustrates selecting at least one artificial sensoryexperience and at least one prescription medication at least partiallybased on a treatment algorithm. For example, as shown in FIG. 1,selector module 106 may select at least one artificial sensoryexperience and at least one prescription medication at least partiallybased on a treatment algorithm. In one instance, selector module 106 canselect an artificial sensory experience and a prescription medicationbased on a computer software treatment algorithm. A treatment algorithmmay include any computation, formula, statistical survey, and/or look-uptable for determining and/or selecting a suitable artificial sensoryexperience and prescription medication combination. Some examples mayinclude a computer software algorithm, a calculator, a flowchart, and/ora decision tree. For example, system 100 and/or selector module 106 may,based on an accepted pain symptom of an individual, access a lookupchart that matches the pain symptom with a pain medication, such asnaproxen, and a virtual experience, such as World of Warcraft. Such acombination therapy may be particularly effective in ameliorating thepain symptom in the individual. In some instances, selector module 106may include a computer processor.

Further, operation 2504 illustrates selecting at least one prescriptionmedication at least partially based on at least one of a drug allergyassociated with the at least one individual or a drug interactionassociated with the at least one prescription medication. For example,as shown in FIG. 1, selector module 106 may select at least oneprescription medication at least partially based on at least one of adrug allergy associated with the at least one individual or a druginteraction associated with the at least one prescription medication. Inone example, selector module 106 can select a prescription medicationbased on a drug allergy associated with the at least one individual. Adrug allergy may include any allergy to a drug and/or drug intolerance.Some examples of a drug allergy may include penicillin allergies,codeine allergies, and/or allergies to a dye in a drug. A druginteraction may include an undesirable and/or unwanted reaction betweentwo or more drugs and/or medications. For example, the system 100 and/orselector module 106 can select a prescription medication other thanthose that might cause a side effect in an individual, perhaps becauseof a known predisposition to the side effect (e.g., an allergy) orbecause of a known drug-drug interaction relevant to the individualbased on the individual's medication regimen. In this way, risk of sideeffects can be lessened. In some instances, selector module 106 mayinclude a computer processor.

Operation 2506 illustrates selecting at least one opioid analgesic andat least one virtual world experience to address at least one painattribute of at least one individual. For example, as shown in FIG. 1,selector module 106 may select from a prescription medication databaseat least one opioid analgesic and at least one virtual world experienceto address at least one pain attribute of at least one individual. Inone example, selector module 106 can select an opioid analgesicincluding morphine and a virtual world experience including an onlinegame to address a pain attribute of at least one individual named MaryAndersen. In some instances, selector module 106 may include a computerprocessor.

FIG. 26 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 26 illustrates example embodiments whereoperation 240 may include at least one additional operation. Additionaloperations may include an operation 2602, an operation 2604, and/or anoperation 2606.

Operation 2602 illustrates presenting an indication of a preferredcombination including at least one prescription medication and at leastone artificial sensory experience and at least one alternativecombination including at least one alternative prescription medicationand at least one alternative artificial sensory experience. For example,as shown in FIG. 1, presenter module 108 may present an indication of apreferred combination including at least one prescription medication andat least one artificial sensory experience and at least one alternativecombination including at least one alternative prescription medicationand at least one alternative artificial sensory experience. In oneinstance, presenter module 108 can present an indication of a preferredcombination to an individual 134 including a prescription medication andan artificial sensory experience along with an alternative combinationincluding an alternative prescription medication and an alternativeartificial sensory experience. Individual 134 may include a singleindividual, multiple individuals, and/or an entity. A preferredcombination may include a more desirable combination due to a lack ofand/or a reduced number of and/or level of side effects, reduced impactupon the administered individual, and/or increased compatibility withanother medications and/or treatment. An alternative combination mayinclude any combination in addition to the preferred combination and maybe ostensibly less desirable than the preferred artificial sensoryexperience because of a potential side effect and/or impact upon theadministered individual. Presentation of alternative combinations mayprovide benefits to the individual in terms of accessibility,affordability, and/or personal preference of medication and/orartificial sensory experience. In some instances, presenter module 108may include a computer processor.

Operation 2604 illustrates presenting an indication of the at least oneprescription medication and the at least one artificial sensoryexperience to at least one output device. For example, as shown in FIG.1, presenter module 108 may present an indication of the at least oneprescription medication and the at least one artificial sensoryexperience to at least one output device. In one example, presentermodule 108 can present an indication of a prescription medication and anartificial sensory experience to an output device 130 including aprinter at a health clinic. An output device may include any hardwaredevice configured for receiving computer output. Some examples of anoutput device may include a printer, a monitor, a mobile phone, aspeaker, and/or a visual display unit. The output device may be used byindividual 134. In some instances, presenter module 108 may include acomputer processor.

Further, operation 2606 illustrates presenting an indication of at leastone of the at least one prescription medication or the at least oneartificial sensory experience to at least one user interface. Forexample, as shown in FIG. 1, presenter module 108 may present anindication of at least one of the at least one prescription medicationor the at least one artificial sensory experience to at least one userinterface. In one instance, presenter module 108 can present anindication of a prescription medication and an artificial sensoryexperience to a user interface. A user interface may include means bywhich an individual may interact with a system. Some examples of a userinterface may include a touchscreen, a graphical user interface, atactile interface, and/or a live user interface. In some instances,presenter module 108 may include a computer processor.

FIG. 27 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 27 illustrates example embodiments whereoperation 240 may include at least one additional operation. Additionaloperations may include an operation 2702. Further, operation 2702illustrates presenting an indication of at least one of the at least oneprescription medication or the at least one artificial sensoryexperience to at least one mobile device. For example, as shown in FIG.1, presenter module 108 may present an indication of at least one of theat least one prescription medication or the at least one artificialsensory experience to at least one mobile device. In one instance,presenter module 108 can present an indication of a prescriptionmedication to a mobile device 132. A mobile device may include aportable computing device and may have wireless connection capability.Some examples of a mobile device may include a laptop or notebookcomputer, a personal digital assistant (PDA), an ipod, a smartphone, anEnterprise digital assistant (EDA), and/or a pager. In some instances,presenter module 108 may include a computer processor.

FIG. 28 illustrates alternative embodiments of the example operationalflow 200 of FIG. 2. FIG. 28 illustrates example embodiments whereoperation 240 may include at least one additional operation. Additionaloperations may include an operation 2802, and/or an operation 2804.

Operation 2802 illustrates presenting to a health care provider anindication of at least one of the at least one prescription medicationor the at least one artificial sensory experience at least partly basedon the selecting at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual. For example, as shown in FIG. 1, presentermodule 108 may present to a health care provider an indication of atleast one of the at least one prescription medication or the at leastone artificial sensory experience at least partly based on the selectingat least one prescription medication and at least one artificial sensoryexperience to address an attribute of an individual. In one example,presenter module 108 can present to a health care provider 128 anindication of a prescription medication based on the selecting at leastone prescription medication and at least one artificial sensoryexperience to address the at least one attribute 120 of at least oneindividual. A health care provider may include a pharmacy, apharmaceutical company, a medical device company, a researchinstitution, a computer software and/or computer hardware company, awebsite, a nurse and/or a physician. In some instances, presenter module108 may include a computer processor.

Operation 2804 illustrates presenting an indication of the at least oneprescription medication or the at least one artificial sensoryexperience at a staggered time. For example, as shown in FIG. 1,presenter module 108 may present an indication of at least one of the atleast one prescription medication or the at least one artificial sensoryexperience at a staggered time. In one example, presenter module 108 canpresent an indication of a series of prescription medications and anartificial sensory experience at staggered times. A staggered time mayinclude presenting an indication of the at least one drug and/orartificial sensory experience at overlapping times and/or at differenttimes, including alternating times. For example, at least one drug andan artificial sensory experience may be administered at an initial timeand the same or a different drug may be administered when thefirst-administered at least one drug is at its peak effect. In anotherexample, at least one drug and an artificial sensory experience may beadministered at an initial time and the same or a different drug may beadministered when the first administered at least one drug is at itslowest effect. In another example, an artificial sensory experience maybe administered at an initial time and at least one prescriptionmedication at a later time. The at least one artificial sensoryexperience and/or the at least one prescription medication may beadministered at any number of times either concurrently, partiallyconcurrently, or not concurrently. In some instances, presenter module108 may include a computer processor.

FIG. 29 illustrates an operational flow 2900 representing exampleoperations related to querying at least one database at least partlybased on at least one attribute of an individual, selecting from the atleast one database at least one prescription medication to address theat least one attribute of at least one individual, and/or implementingat least one artificial sensory experience to address the at least oneattribute of at least one individual in response to a selected at leastone prescription medication. In FIG. 29, discussion and explanation maybe provided with respect to the above-described examples of FIG. 1,and/or with respect to other examples and contexts. However, it shouldbe understood that the operational flows may be executed in a number ofother environments and contexts, and/or in modified versions of FIG. 1.Also, although the various operational flows are presented in thesequence(s) illustrated, it should be understood that the variousoperations may be performed in other orders than those which areillustrated, or may be performed concurrently.

After a start operation, the operational flow 2900 moves to an operation2910. Operation 2910 depicts querying at least one database at leastpartly based on at least one attribute of an individual. For example, asshown in FIG. 1, querier module 104 may search at least one database atleast partly based on at least one attribute of an individual. In oneinstance, querier module 104 may search medication database 124 andartificial sensory experience database 126 based on an attribute 120including an indication of hypertension associated with an individualnamed John Smith. In some instances, querier module 104 may include acomputer processor.

Then, operation 2920 depicts selecting from the at least one database atleast one prescription medication to address the at least one attributeof at least one individual. For example, as shown in FIG. 1, selectormodule 106 may select from the at least one database at least oneprescription medication to address the at least one attribute of atleast one individual. In one example and continuing with the previousexample, selector module 106 may select from medication database 124 andartificial sensory experience database 126 a prescription medicine foraddressing the attribute 120 including an indication of hypertensionassociated with an individual named John Smith. In some instances,selector module 106 may include a computer processor.

Then, operation 2930 depicts implementing at least one artificialsensory experience to address the at least one attribute of at least oneindividual in response to a selected at least one prescriptionmedication. For example, as shown in FIG. 1, implementer module 138 mayimplement at least one artificial sensory experience to address the atleast one attribute of at least one individual in response to a selectedat least one prescription medication. In one instance and continuingwith the previous example, implementer module 106 may implement anartificial sensory experience including a virtual world for addressingthe attribute 120 including an indication of hypertension associatedwith an individual named John Smith in response to a selectedprescription medication from a medication database 124. In someinstances, selector module 106 may include a computer processor.

FIG. 30 illustrates a partial view of an example computer programproduct 3000 that includes a computer program 3004 for executing acomputer process on a computing device. An embodiment of the examplecomputer program product 3000 is provided using a signal-bearing medium3002, and may include one or more instructions for accepting at leastone attribute of at least one individual; one or more instructions forquerying at least one database at least partly based on the at least oneattribute; one or more instructions for selecting from the at least onedatabase at least one prescription medication and at least oneartificial sensory experience to address the at least one attribute ofat least one individual; and one or more instructions for presenting anindication of the at least one prescription medication and the at leastone artificial sensory experience at least partly based on the selectingfrom the at least one database at least one prescription medication andat least one artificial sensory experience to address the at least oneattribute of at least one individual. The one or more instructions maybe, for example, computer executable and/or logic-implementedinstructions. In one implementation, the signal-bearing medium 3002 mayinclude a computer-readable medium 3006. In one implementation, thesignal bearing medium 3002 may include a recordable medium 3008. In oneimplementation, the signal bearing medium 3002 may include acommunications medium 3010.

FIG. 31 illustrates an example system 3100 in which embodiments may beimplemented. The system 3100 includes a computing system environment.The system 3100 also illustrates the user 118 using a device 3104, whichis optionally shown as being in communication with a computing device3102 by way of an optional coupling 3106. The optional coupling 3106 mayrepresent a local, wide-area, or peer-to-peer network, or may representa bus that is internal to a computing device (e.g., in exampleembodiments in which the computing device 3102 is contained in whole orin part within the device 3104). A storage medium 3108 may be anycomputer storage media.

The computing device 3102 includes computer-executable instructions 3110that when executed on the computing device 3102 cause the computingdevice 3102 to accept at least one attribute of at least one individual;query at least one database at least partly based on the at least oneattribute; select from the at least one database at least oneprescription medication and at least one artificial sensory experienceto address the at least one attribute of at least one individual; andpresent an indication of the at least one prescription medication andthe at least one artificial sensory experience at least partly based onthe selecting from the at least one database at least one prescriptionmedication and at least one artificial sensory experience to address theat least one attribute of at least one individual. As referenced aboveand as shown in FIG. 31, in some examples, the computing device 3102 mayoptionally be contained in whole or in part within the device 3104.

In FIG. 31, then, the system 3100 includes at least one computing device(e.g., 3102 and/or 3104). The computer-executable instructions 3110 maybe executed on one or more of the at least one computing device. Forexample, the computing device 3102 may implement the computer-executableinstructions 3110 and output a result to (and/or receive data from) thecomputing device 3104. Since the computing device 3102 may be wholly orpartially contained within the computing device 3104, the device 3104also may be said to execute some or all of the computer-executableinstructions 3110, in order to be caused to perform or implement, forexample, various ones of the techniques described herein, or othertechniques.

The device 3104 may include, for example, a portable computing device,workstation, or desktop computing device. In another example embodiment,the computing device 3102 is operable to communicate with the device3104 associated with the user 118 to receive information about the inputfrom the user 118 for performing data access and data processing andpresenting an output of the user-health test function at least partlybased on the user data.

Although a user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that a user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents). In addition, a user 118, asset forth herein, although shown as a single entity may in fact becomposed of two or more entities. Those skilled in the art willappreciate that, in general, the same may be said of “sender” and/orother entity-oriented terms as such terms are used herein.

FIG. 32 illustrates system 3200 for accepting an indication of aschedule for administration of a bioactive agent to an individual,presenting an indication of an artificial sensory experience at leastpartly based on the accepting an indication of the schedule foradministration of the bioactive agent to the individual, and/oraccepting an indication of at least one of a pharmacokinetic orpharmacodynamic profile of a bioactive agent. The system 3200 mayinclude accepter module 3402, presenter module 3410, profile acceptermodule 3452, monitoring unit 3202, determiner module 3482, and/oradministration unit 3222. Administration unit 3222 may include physicalintervention effector module 3224 and/or artificial sensory experienceeffector module 3226. Monitoring unit 3202 may include drug sensing unit3204, physiologic activity monitor 3206, brain activity measurement unit3208, behavior monitor 3210, instrumentation monitor 3212, compliancereporting unit 3214, voice response module 3216, hearing test module3218, and/or scale 3220. Additionally, system 3200 may include mobiledevice 132.

FIG. 33 illustrates system 3200 for accepting an indication of aschedule for administration of a bioactive agent to an individual,presenting an indication of an artificial sensory experience at leastpartly based on the accepting an indication of the schedule foradministration of the bioactive agent to the individual, and/oraccepting an indication of at least one of a pharmacokinetic orpharmacodynamic profile of a bioactive agent. The system 3200 mayinclude accepter module 3402, presenter module 3410, profile acceptermodule 3452, determiner module 3482, monitoring unit 3202, and/oradministration unit 3222. Accepter module 3402 may receive and/ortransmit information and/or data to and/or from user 118, database 122,presenter module 3410, profile accepter module 3452, and/or health careprovider 136. Database 122 may include medication database 124 and/orartificial sensory experience database 126. Monitoring unit 3202 maymonitor individual 134 and may include drug sensing unit 3204,physiologic activity monitor 3206, brain activity measurement unit 3208,behavior monitor 3210, instrumentation monitor 3212, compliancereporting unit 3214, voice response module 3216, hearing test module3218, and/or scale 3220. Administration unit 3222 may include physicalintervention effector module 3224 and/or artificial sensory experienceeffector module 3226. Additionally, mobile device 132 may communicatewith acceptor module 3402, presenter module 3410, profile acceptermodule 3452, healthcare provider 136, user 118, individual 134,monitoring unit 3202, and/or administration unit 3222.

FIG. 34 further illustrates system 3200 including accepter module 3402and/or presenter module 3410. Accepter module 3402 may include timeschedule accepter module 3404, bioactive agent schedule accepter module3406, and/or dose accepter module 3408. Presenter module 3410 mayinclude prescription presenter module 3412, algorithm utilizer module3426, medical history presenter module 3434, experimental data presentermodule 3436, medical reference tool presenter module 3438, output devicepresenter module 3440, and/or third party presenter module 3446.Prescription presenter module 3412 may include effect presenter module3414, effectiveness presenter module 3420, concentration presentermodule 3422, and/or recommender module 3424. Effect presenter module3414 may include desired effect presenter module 3416 and/or adverseeffect presenter module 3418. Algorithm utilizer module 3426 may includepharmacokinetic software utilizer module 3428, pharmacodynamic softwareutilizer module 3430, and/or contraindication algorithm utilizer module3432. Output device presenter module 3440 may include user interfacepresenter module 3442 and/or mobile device presenter module 3444. Thirdparty presenter module 3446 may include health care provider presentermodule 3448 and/or selective presenter module 3450.

FIG. 35 further illustrates system 3200 including accepter module 3402,presenter module 3428, profile accepter module 3452, and/or determinermodule 3482. Profile accepter module 3452 may include concentrationrepresentation accepter module 3454, response representation acceptermodule 3456, plasma concentration accepter module 3458, bioavailabilityprofile accepter module 3460, model accepter module 3462, characteristicaccepter module 3470, attribute profile accepter module 3472, and/orparameter accepter module 3480. Model accepter module 3462 may includephysiological model accepter module 3464, in vitro model accepter module3466, and/or software output accepter module 3468. Attribute profileaccepter module 3472 may include physiological characteristic acceptermodule 3474, medical history profile accepter module 3476, and/or groupattribute accepter module 3478.

System 3200 generally represents instrumentality for accepting anindication of a schedule for administration of a bioactive agent to anindividual, presenting an indication of an artificial sensory experienceat least partly based on the accepting an indication of the schedule foradministration of the bioactive agent to the individual, and/oraccepting an indication of at least one of a pharmacokinetic orpharmacodynamic profile of a bioactive agent. The operations ofaccepting an indication of a schedule for administration of a bioactiveagent to an individual, presenting an indication of an artificialsensory experience at least partly based on the accepting an indicationof the schedule for administration of the bioactive agent to theindividual, and/or accepting an indication of at least one of apharmacokinetic or pharmacodynamic profile of a bioactive agent may beaccomplished electronically, such as with a set of interconnectedelectrical components, an integrated circuit, and/or a computerprocessor.

FIG. 36 illustrates an operational flow 3600 representing exampleoperations related to accepting an indication of a schedule foradministration of a bioactive agent to an individual and/or presentingan indication of an artificial sensory experience at least partly basedon the accepting an indication of the schedule for administration of thebioactive agent to the individual. In FIG. 36 and in following figuresthat include various examples of operational flows, discussion andexplanation may be provided with respect to the above-described examplesof FIGS. 32 through 35, and/or with respect to other examples andcontexts. However, it should be understood that the operational flowsmay be executed in a number of other environments and contexts, and/orin modified versions of FIGS. 32 through 35. Also, although the variousoperational flows are presented in the sequence(s) illustrated, itshould be understood that the various operations may be performed inother orders than those which are illustrated, or may be performedconcurrently.

After a start operation, the operational flow 3600 moves to operation3610. Operation 3610 depicts accepting an indication of a schedule foradministration of a bioactive agent to an individual. For example, asshown in FIGS. 32 through 35, accepter module 3402 may accept anindication of a schedule for administration of a bioactive agent to anindividual. In one embodiment, accepter module 3402 may accept anindication of a schedule for an intravenous administration of an opioidto an individual. In this embodiment, the schedule may include specifictimes and/or methods that the bioactive agent may be administered. Forexample, a time schedule may specify that an individual should receive aspecific dose of morphine every two hours. In another example, anadministration schedule may specify that an opioid should beadministered intravenously at night and orally during waking hours. Insome instances, accepter module 3402 may include a computer processorand/or a user interface coupled to the computer processor.

Then, operation 3620 depicts presenting an indication of an artificialsensory experience at least partly based on the accepting an indicationof the schedule for administration of the bioactive agent to theindividual. For example, as shown in FIGS. 32 through 35, presentermodule 3410 may present an indication of an artificial sensoryexperience at least partly based on the accepting an indication of theschedule for administration of the bioactive agent to the individual. Inone embodiment, presenter module 3410 may present an indication of avirtual world configured for distracting an individual at least partlybased on accepting an indication of a bioactive agent administrationtime schedule. In this embodiment, the bioactive administration schedulemay be coordinated so that an artificial sensory experience isadministered when a bioactive agent may be less effective. Coordinatingan artificial sensory experience administration schedule may serve tomore efficiently distract and/or reduce, for example, an individual'spain during a period of low bioactive agent concentration in anindividual's blood. In some instances, presenter module 3410 may includea computer processor, a display, and/or a printer.

FIG. 37 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 37 illustrates example embodiments whereoperation 3610 may include at least one additional operation. Additionaloperations may include operation 3702, operation 3704, and/or operation3706.

Operation 3702 illustrates accepting a bioactive agent time schedule.For example, as shown in FIGS. 32 through 35, time schedule acceptermodule 3404 may accept a bioactive agent time schedule. In oneembodiment, accepter module 3404 may accept a bioactive agent timeschedule which specifies that an opioid, such as morphine, should beadministered every two hours. A bioactive agent time schedule mayspecify, for example, the exact and/or appropriate time a bioactiveagent should be administered. Additionally, a bioactive agent timeschedule may specify different bioactive agents and/or combinations ofbioactive agents, delivery methods for administering a bioactive agent,and/or bioactive agent dosage. Accepting a bioactive agent time schedulemay include accepting from a computer processor, accepting from a memorydevice, and/or accepting from a user input. In one example, acceptermodule 3404 may accept a bioactive agent time schedule configured forprinting on a medication blister pack, such as that described inSteinnagel, U.S. Pat. No. 4,974,729, which is incorporated herein byreference. In an additional example, accepter module 3404 may accept abioactive agent time schedule from a device configured to remind anindividual when to take medication, such as that in Goetz, U.S. Pat. No.6,314,384, which is incorporated herein by reference. In some instances,accepter module 3404 may include a computer processor.

Operation 3704 illustrates accepting at least one of a bioactive agentdelivery type or bioactive agent delivery dosage administrationschedule. For example, as shown in FIGS. 32 through 35, bioactive agentschedule accepter module 3406 may accept at least one of a bioactiveagent delivery type schedule or a bioactive agent delivery dosageadministration schedule. Accepting a bioactive agent time schedule mayinclude accepting from a computer processor, accepting from a memorydevice, and/or accepting from a user input. In one embodiment, bioactiveagent schedule accepter module 3406 may accept a bioactive agentdelivery type schedule specifying an intravenous administration of anopioid. In this embodiment, the bioactive agent time schedule mayindicate that the opioid only be administered intravenously. In anotherembodiment, bioactive agent schedule accepter module 3406 may accept abioactive agent delivery dosage specifying a first opioid administrationdosage for a first time period, such as during an individual's awakehours, and a second opioid administration dosage for a second timeperiod, such as during an individual's sleeping hours. In someinstances, bioactive agent schedule accepter module 3406 may include acomputer processor.

Operation 3706 illustrates accepting a bioactive agent loading dose. Forexample, as shown in FIGS. 32 through 35, dose accepter module 3408 mayaccept a bioactive agent loading dose. A loading dose may include aninitial dose that is higher than a maintenance and/or average dose.Often, a loading dose may be used for a bioactive agent that iseliminated from an individual's body slowly. In one embodiment, doseaccepter module 3408 may accept a phenytoin sodium loading dose fortreatment of epileptic seizures. Some other bioactive agents a loadingdose may be used with may include digoxin, teicoplanin, voriconazole,and/or procainamide. In some instances, dose accepter module 3408 mayinclude a computer processor.

FIG. 38 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 38 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 3802, operation 3804, operation 3806,and/or operation 3808.

Operation 3802 illustrates presenting an indication of a prescribedartificial sensory experience. For example, as shown in FIGS. 32 through35, prescription presenter module 3412 may present an indication of aprescribed artificial sensory experience. A prescribed artificialsensory experience may include any artificial sensory experienceprescribed by a health care professional, such as a physician, a mentalhealth specialist, a nurse, a physical therapist, an occupationaltherapist, a chiropractor, and/or a homeopathic practitioner. In oneembodiment, prescription presenter module 3412 may present an indicationof a virtual world prescribed by a psychiatrist. In this embodiment, theprescribed virtual world may be configured to be administered inconjunction with a prescribed bioactive agent. Administering aprescribed bioactive agent in conjunction with a prescribed artificialsensory experience may serve to increase efficacy of the combinedtherapy, for example, by serving as a distraction from pain. In someinstances, prescription presenter module 3412 may include a computerprocessor and/or a display device, such as a computer monitor and/or aprinter.

Further, operation 3804 illustrates presenting an indication of at leastone effect of the prescribed artificial sensory experience. For example,as shown in FIGS. 32 through 35, effect presenter module 3414 maypresent an indication of at least one effect of the prescribedartificial sensory experience. In one embodiment, effect presentermodule 3414 may present an indication of at least one effect of theprescribed artificial sensory experience. An effect may include areaction and/or thing that occurs as a result of the artificial sensoryexperience. For example, an effect may include a side effect, a desiredeffect, and/or an adverse effect. Some examples of an effect may includean increased bioactive agent efficacy, dizziness, and/or a decreasedheart rate. In some instances, effect presenter module 3414 may includea computer processor.

Further, operation 3806 illustrates presenting an indication of at leastone desired effect of the prescribed artificial sensory experience. Forexample, as shown in FIGS. 32 through 35, desired effect presentermodule 3416 may present an indication of at least one desired effect ofthe prescribed artificial sensory experience. Some examples of a desiredeffect may include effects such as an increased bioactive agentefficacy, a cured illness and/or condition, and/or a changed behavior.In one embodiment, desired effect presenter module 3416 may present anindication of an increased opioid efficacy measured by self painevaluation by an individual. In some instances, desired effect presentermodule 3416 may include a computer processor and/or a display, such as amonitor and/or a printer.

Further, operation 3808 illustrates presenting an indication of at leastone expected adverse effect of the prescribed artificial sensoryexperience. For example, as shown in FIGS. 32 through 35, adverse effectpresenter module 3418 may present an indication of an expected adverseeffect of the prescribed artificial sensory experience. An adverseeffect may include a harmful and/or undesired effect resulting from anintervention, such as an artificial sensory experience. Some examples ofan adverse effect may include headache, dizziness, depression, bleeding,seizure, and/or fever. In one embodiment, adverse effect presentermodule 3418 may present an indication of fever in an individual whilebeing administered a prescribed artificial sensory experience andbioactive agent. In some instances, adverse effect presenter module 3418may include a computer processor, a display device, such as a monitorand/or printer, and/or medical instrumentation, such as a thermometerconfigured for measuring a body temperature.

FIG. 39 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 39 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 3902, operation 3904, and/or operation3906. Further, operation 3902 illustrates presenting an indication of atleast one time period of an expected change in bioactive agenteffectiveness. For example, as shown in FIGS. 32 through 35,effectiveness presenter module 3420 may present an indication of atleast one time period of an expected change in bioactive agenteffectiveness. In one embodiment, effectiveness presenter module 3420may present an indication of a time period when an opioid is expected todecrease in effectiveness. Such an indication of decrease and/or changein bioactive agent effectiveness may serve to indicate an appropriatetime period for administering and/or modifying an artificial sensoryexperience to compensate for a change in bioactive agent efficacy. Inanother embodiment, effectiveness presenter module 3420 may present anindication of a time period where a blood stream morphine concentrationdrops. This time period of low blood stream morphine concentration maybe appropriate for presenting an immersive virtual world for serving asa distraction to any increase in pain caused by lowered morphineconcentration. In some instances, effectiveness presenter module 3420may include a computer processor.

Further, operation 3904 illustrates presenting an indication of at leastone time period of an expected change in bioactive agent bloodconcentration. For example, as shown in FIGS. 32 through 35,concentration presenter module 3422 may present an indication of atleast one time period of an expected change in bioactive agent bloodconcentration. In one embodiment, concentration presenter module 3422may present an indication of a one hour time period of an expectedchange in hydrocodone blood concentration. Indicating a time period of achange in blood concentration may serve to help determine an artificialsensory experience administration schedule. For example, if a bioactiveagent blood concentration is expected to be reduced during a certaintime period, an artificial sensory experience configured for distractingan individual from pain may be selected for administration during thattime period. In some instances, concentration presenter module 3422 mayinclude a computer processor and/or a display device, such as a printerand/or a computer monitor.

Further, operation 3906 illustrates recommending an artificial sensoryexperience administration schedule. For example, as shown in FIGS. 32through 35, recommender module 3424 may recommend an artificial sensoryexperience administration schedule. In one embodiment, recommendermodule 3424 may recommend a time schedule for administration of avirtual world experience. A time schedule may be recommended by takinginto account factors involving the individual and/or the bioactiveagent. For example, efficacy of the bioactive agent versus time may be afactor, such as a time period when the bioactive agent is lesseffective. Efficacy of the bioactive agent may be a factor indetermining when an artificial sensory experience is administeredbecause of the potential for the artificial sensory experience tocompensate for a changed bioactive agent efficacy. An additional factormay include an attribute of the individual, such as how a bioactiveagent and/or specific artificial sensory experience affects theindividual, for example a side effect. Another example of recommendingan artificial sensory experience may be found in Akazawa et al., U.S.Pat. No. 7,155,680, which is incorporated herein by reference. In someinstances, recommender module 3424 may include a computer processor.

FIG. 40 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 40 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4002, operation 4004, operation 4006,and/or operation 4008.

Operation 4002 illustrates utilizing an algorithm for recommending atleast one artificial sensory experience. For example, as shown in FIGS.32 through 35, algorithm utilizer module 3426 may utilize an algorithmfor recommending at least one artificial sensory experience. Analgorithm for recommending an artificial sensory experience may includeany computation, formula, statistical survey, and/or look-up table fordetermining and/or selecting a suitable artificial sensory experience.Some examples may include a computer software algorithm, a calculator, aflowchart, and/or a decision tree. In one embodiment, algorithm utilizermodule 3426 may utilize an algorithm that uses an inputted indication ofan analgesic, such as oxycodone, and determines a suitable artificialsensory experience by analyzing periods of low blood concentration ofthe oxycodone. In this embodiment, algorithm utilizer module 3426 mayrecommend an artificial sensory experience that may be effective in paindistraction when bioactive agent blood concentration may be reduced butbefore an additional dose may be available. In some instances, algorithmutilizer module 3426 may include a computer processor.

Further, operation 4004 illustrates utilizing pharmacokinetic modelingsoftware. For example, as shown in FIGS. 32 through 35, pharmacokineticsoftware utilizer module 3428 may utilize pharmacokinetic modelingsoftware. In one embodiment, pharmacokinetic software utilizer module3428 may utilize modeling software to determine and displaycharacteristics regarding a specific bioactive agent. Pharmacokineticmodeling software may include software configured for displayingpharmacokinetic information for a specific bioactive agent, such as apharmacokinetic profile. Additionally, pharmacokinetic modeling softwaremay analyze and compare a specific bioactive agent and/or apharmacokinetic profile with an artificial sensory experience and make arecommendation based on, for example, low bioactive blood concentration.An additional example of utilizing pharmacokinetic modeling software maybe found in Bachman et al., U.S. Patent Publication No. 2006/0161408,which is incorporated herein by reference. Some examples ofpharmacokinetic software may include acslXtreme, available from AegisTechnologies Group, Inc., West Austin, Tex., and GastroPlus, availablefrom Simulations Plus, Inc., Lancaster, Calif. In some instances,pharmacokinetic software utilizer module 3428 may include a computerprocessor. Further, operation 4006 illustrates utilizing pharmacodynamicmodeling software. For example, as shown in FIGS. 32 through 35,pharmacodynamic software utilizer module 3430 may utilizepharmacodynamic modeling software. In one embodiment, pharmacodynamicsoftware utilizer module 3430 may utilize pharmacodynamic modelingsoftware for determining an appropriate artificial sensory experiencebased on how a specific bioactive agent, such as morphine, affects anindividual. Utilizing pharmacodynamic software may be useful fordetermining an appropriate artificial sensory experience that maycompensate for a period of low bioactive agent blood concentration. Anappropriate artificial sensory experience may compensate for reducedbioactive agent efficacy by acting as a distraction when the bioactiveagent concentration may be reduced. One example of pharmacodynamicmodeling software may include GastroPlus, available from SimulationsPlus, Inc., Lancaster, Calif. In some instances, pharmacodynamicsoftware utilizer module 3430 may include a computer processor.

Further, operation 4008 illustrates utilizing an algorithm configuredfor identifying a contraindication of the artificial sensory experience.For example, as shown in FIGS. 32 through 35, contraindication algorithmutilizer module 3432 may utilize an algorithm configured for identifyinga contraindication of the artificial sensory experience. Acontraindication of an artificial sensory experience may include givingan indication against the advisability of the artificial sensoryexperience. For example, contraindication algorithm utilizer module 3432may utilize an algorithm that considers an individual's personal medicalhistory, such as a phobia, and may recommend not prescribing a certainartificial sensory experience, which may include an object that maytrigger the phobia. Contraindication algorithm utilizer module 3432 mayidentify a contraindication of an artificial sensory experience forreasons such as an adverse effect and/or inefficacy. In some instances,contraindication algorithm utilizer module 3432 may include a computerprocessor.

FIG. 41 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 41 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4102, operation 4104, and/or operation4106.

Operation 4102 illustrates presenting an indication of an artificialsensory experience at least partly based on a personal medical history.For example, as shown in FIGS. 32 through 35, medical history presentermodule 3434 may present an indication of an artificial sensoryexperience at least partly based on a personal medical history. Amedical history may include a personal history and/or a family history.A personal medical history may include a list of previous illnesses,symptoms, medicines, treatments, health risk factors, operations, and/ordoctor visits associated with at least one individual. A personal and/ora family medical history may include life history and/or social historycharacteristics such as smoking, drinking, drug use, sexual history,exercise history, eating history, nutraceutical history, or the like. Inone embodiment, medical history presenter module 3434 may present anindication of a suitable virtual world based on a personal medicalhistory. In this embodiment, the personal medical history may indicatethat an individual may be averse to a certain virtual world, such as avirtual world with rapid animation that may cause nausea. In someinstances, medical history presenter module 3434 may include a computerprocessor and/or a display device, such as a computer monitor and/or aprinter.

Operation 4104 illustrates presenting an indication of an artificialsensory experience at least partly based on experimental data. Forexample, as shown in FIGS. 32 through 35, experimental data presentermodule 3436 may present an indication of an artificial sensoryexperience at least partly based on experimental data. Experimental datamay include any data from an experiment, such as a clinical trial. Theexperiment may be an experiment including an individual and/or a groupof people. In one embodiment, experimental data presenter module 3436may present an indication of a virtual world suitable for an individualbased on a clinical trial involving a group of 1,000 people showing acertain success rate for reducing a phobia, such as fear of heights. Insome instances, experimental data presenter module 3436 may include acomputer processor and/or a display device, such as a computer monitor,a mobile phone, and/or a printer.

Operation 4106 illustrates presenting an indication of an artificialsensory experience at least partly based on a medical reference tool.For example, as shown in FIGS. 32 through 35, medical reference toolpresenter module 3438 may present an indication of an artificial sensoryexperience at least partly based on a medical reference tool. A medicalreference tool may include a reference book, a reference database,and/or reference software. Some examples of a medical reference book mayinclude a medical dictionary, a medical journal, and/or a book of druginteractions. One example of a reference database may include theNational Cancer Center Cancer Image Reference (NCC-CIR) database and/orDynaMed. Some examples of reference software may include Skyscapesoftware for a mobile phone and/or MedAlert. In one embodiment, medicalreference tool presenter module 3438 may present an indication of anartificial sensory experience based on a reference database, such as adatabase including data from a clinical trial. In some instances,medical reference tool presenter module 3438 may include a computerprocessor and/or a display device, such as a mobile phone, a printer,and/or a computer monitor.

FIG. 42 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 42 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4202, operation 4204, and/or operation4206.

Operation 4202 illustrates presenting the indication to at least oneoutput device. For example, as shown in FIGS. 32 through 35, outputdevice presenter module 3440 may present to at least one output device.In one example, output device presenter module 3440 may present anindication of a combination prescription medication and an artificialsensory experience therapy to an output device 130, such as a printerand/or monitor at a health clinic. An output device may include anyhardware device configured for receiving computer output. Some examplesof an output device may include a printer, a monitor, a mobile phone, aspeaker, and/or a visual display unit. The output device 130 may be usedby individual 134. In some instances, output device presenter module3440may include a computer processor.

Further, operation 4204 illustrates presenting the indication to atleast one user interface. For example, as shown in FIGS. 32 through 35,user interface presenter module 3442 may present to at least one userinterface. In one embodiment, user interface presenter module 3442 maypresent to a touchscreen device. A user interface may include means bywhich an individual may interact with a system. Some examples of a userinterface may include a touchscreen, a graphical user interface, atactile interface, and/or a live user interface. In some instances, userinterface presenter module 3442 may include a computer processor.

Further, operation 4206 illustrates presenting the indication to atleast one mobile device. For example, as shown in FIGS. 32 through 35,mobile device presenter module 3444 may present to at least one mobiledevice. In one embodiment, mobile device presenter module 3444 maypresent to a mobile phone. A mobile device may include a portablecomputing device and may have wireless connection capability. Someexamples of a mobile device may include a laptop or notebook computer, apersonal digital assistant (PDA), an ipod, a smartphone, an Enterprisedigital assistant (EDA), and/or a pager. In some instances, mobiledevice presenter module 3444 may include a computer processor.

FIG. 43 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 43 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include operation 4302, operation 4304, and/or operation4306.

Operation 4302 illustrates presenting the indication to a third party.For example, as shown in FIGS. 32 through 35, third party presentermodule 3446 may present to an individual's physician. A third party mayinclude a party that is an independent party, person, and/or entity.Some examples of a third party may include a physician, a medicaldatabase, a hospital, a law enforcement agency, and/or a pharmacy. Oneexample of reporting to a third party may include creating displays andreports for aggregating data from therapy results, further discussed inBair et al., U.S. Pat. No. 6,067,523, which is incorporated herein byreference. In some instances, third party presenter module 3446 mayinclude a computer processor and/or a communications device, such as amonitor and network link.

Further, operation 4304 illustrates presenting the indication to ahealth care provider. For example, as shown in FIGS. 32 through 35,health care provider presenter module 3448 may present to a health careprovider. A health care provider may include a pharmacy, apharmaceutical company, a medical device company, a researchinstitution, a computer software and/or computer hardware company, awebsite, a nurse and/or a physician. In one embodiment, health careprovider presenter module 3448 may present to a physician a prescribedcombination artificial sensory experience and bioactive agent therapyvia a secured website. In some instances, health care provider presentermodule 3448 may include a computer processor.

Further, operation 4306 illustrates selectively presenting theindication only to the individual. For example, as shown in FIGS. 32through 35, selective presenter module 3450 may selectively present onlyto the individual. Selective presenting may include limiting and/orblocking access of an individual's compliance results and/or aprescribed therapy, such as a prescribed artificial sensory experienceand/or bioactive agent to a specific party. For example, selectivepresenter module 3450 may present only to individual 134 and may keepresults of a certain combination therapy confidential. In oneembodiment, an encryption key may be employed to protect selectedinformation. In an additional example, selective presenter module 3450may report only to a law enforcement agency and/or representative, suchas a probation officer, and not to individual 134. In some instances,selective presenter module 3450 may include a computer processor.

FIG. 44 illustrates alternative embodiments of the example operationalflow 3600 of FIG. 36. FIG. 44 illustrates example embodiments whereoperation 3620 may include at least one additional operation. Additionaloperations may include an operation 4402.

Operation 4402 illustrates accepting the pharmacokinetic profile ofimmediate release oxycodone, accepting a prescribed administrationschedule of the immediate release oxycodone to an individual, andpresenting a prescription for engagement of the individual with avirtual world experience at times when the plasma concentration of theimmediate release oxycodone is expected to be below a substantiallyeffective level based on the pharmacokinetic profile of the immediaterelease oxycodone and the prescribed administration schedule of theimmediate release oxycodone. For example, as shown in FIGS. 32 through35, accepter module 3402 and presenter module 3410 may accept thepharmacokinetic profile of immediate release oxycodone, accept aprescribed administration schedule of the immediate release oxycodone toan individual, and present a prescription for engagement of theindividual with a virtual world experience at times when the plasmaconcentration of the immediate release oxycodone is expected to be belowa substantially effective level based on the pharmacokinetic profile ofthe immediate release oxycodone and the prescribed administrationschedule of the immediate release oxycodone. In some instances, acceptermodule 3402 and presenter module 3410 may include, for example, acomputer processor, a printer, a handheld mobile device, and/or acomputer display.

FIG. 45 illustrates an operational flow 4500 representing exampleoperations related to accepting an indication of a schedule foradministration of a bioactive agent to an individual, presenting anindication of an artificial sensory experience at least partly based onthe accepting an indication of the schedule for administration of thebioactive agent to the individual, and accepting an indication of atleast one of a pharmacokinetic or pharmacodynamic profile of a bioactiveagent. FIG. 45 illustrates an example embodiment where the exampleoperational flow 3600 of FIG. 36 may include at least one additionaloperation. Additional operations may include operation 4510, operation4512, and/or operation 4514.

After a start operation, operation 3610, and operation 3620, theoperational flow 4500 moves to operation 4510. Operation 4510illustrates accepting an indication of at least one of a pharmacokineticor pharmacodynamic profile of a bioactive agent. For example, as shownin FIGS. 32 through 35, profile accepter module 3452 may accept anindication of a pharmacokinetic and/or a pharmacodynamic profile of abioactive agent. A bioactive agent pharmacokinetic profile may includeinformation regarding how the bioactive agent is affected by the body. Apharmacokinetic profile may include information such as absorption,distribution, metabolism, and/or elimination. A bioactive agentpharmacodynamic profile may include information regarding how abioactive agent is affected by the body, such as routes and/ormechanisms of bioactive agent absorption and excretion, the bioactiveagent biotransformation in the body, and/or the rate of a bioactiveagent action. In one embodiment, profile accepter module 3452 may acceptan indication of a pharmacokinetic profile for codeine including, forexample, a metabolism rate. In another embodiment, profile acceptermodule 3452 may accept an indication of a pharmacodynamic profile formethadone. In some instances, profile accepter module 3452 may include acomputer processor and/or a user interface.

Operation 4512 illustrates accepting an indication of a time versusconcentration representation for a bioactive agent. For example, asshown in FIGS. 32 through 35, concentration representation acceptermodule 3454 may accept an indication of a time versus concentrationrepresentation for a bioactive agent. In one embodiment, concentrationrepresentation accepter module 3454 may accept an indication of a timeversus concentration representation for a regiment of prescribedmorphine. A time versus concentration representation may serve toindicate time periods of reduced and/or changed bioactive agenteffectiveness. A determination of reduced and/or changed bioactive agenteffectiveness may indicate a suitable time period for administering anartificial sensory experience, which may serve as an additionaldistraction and/or compensation. In some instances, concentrationrepresentation accepter module 3454 may include a computer processor.

Operation 4514 illustrates accepting an indication of a dose versusresponse representation for a bioactive agent. For example, as shown inFIGS. 32 through 35, response representation accepter module 3456 mayaccept an indication of a dose versus response representation for abioactive agent. In one embodiment, response representation acceptermodule 3456 may accept an indication of a dose versus responserepresentation for fluoxetine hydrochloride. A dose versus responserepresentation may serve to indicate a proper bioactive agent dosage fora desired response of an individual while the individual experiences anartificial sensory experience. In some instances, responserepresentation accepter module 3456 may include a computer processor.

FIG. 46 illustrates alternative embodiments of the example operationalflow 4500 of FIG. 45. FIG. 46 illustrates example embodiments whereoperation 4510 may include at least one additional operation. Additionaloperations may include operation 4602, and/or operation 4604.

Operation 4602 illustrates accepting a depiction of an area under plasmaconcentration versus time curve for the bioactive agent. For example, asshown in FIGS. 32 through 35, plasma concentration accepter module 3458may accept a depiction of an area under plasma concentration versus timecurve for the bioactive agent. In one embodiment, plasma concentrationaccepter module 3458 may accept a depiction of an area under plasmaconcentration versus time curve for fentanyl. An area under plasmaconcentration versus time curve may be useful for determining anappropriate time period to administer an artificial sensory experienceconfigured to serve as a distraction and compensate for a reducedbioactive agent efficacy. In some instances, plasma concentrationaccepter module 3458 may include a computer processor.

Operation 4604 illustrates accepting a bioavailability profile for thebioactive agent. For example, as shown in FIGS. 32 through 35,bioavailability profile accepter module 3460 may accept abioavailability profile for the bioactive agent. In one embodiment,bioavailability profile accepter module 3460 may accept abioavailability profile for hydromorphone. A bioavailability profile mayinclude information describing the fraction of a bioactive agent dosethat may reach systemic circulation in an unchanged state or istherapeutically active. In another embodiment, bioavailability profileaccepter module 3460 may accept a bioavailability profile for acombination hydrocodone/paracetamol oral medication. In some instances,bioavailability profile accepter module 3460 may include a computerprocessor.

FIG. 47 illustrates alternative embodiments of the example operationalflow 4500 of FIG. 45. FIG. 47 illustrates example embodiments whereoperation 4510 may include at least one additional operation. Additionaloperations may include operation 4702, operation 4704, operation 4706,and/or operation 4708.

Operation 4702 illustrates accepting a pharmacokinetic model. Forexample, as shown in FIGS. 32 through 35, model accepter module 3462 mayaccept a pharmacokinetic model. A pharmacokinetic profile may includeinformation regarding bioactive agent absorption, distribution,metabolism, and/or elimination. In one embodiment, model accepter module3462 may accept a pharmacokinetic model including a model derived bycomputer software. A pharmacokinetic model may include, for example, aone-compartment model or a two-compartment model. A one-compartmentmodel may be suitable for a bioactive agent that rapidly equilibrates ina tissue compartment. A two-compartment model may be suitable for abioactive agent that slowly equilibriates in a tissue compartment.Additionally, a pharmacokinetic model may be presented as a data plot,such as a plot of plasma drug concentration versus time. In someinstances, model accepter module 3462 may include a computer processor.

Further, operation 4704 illustrates accepting a physiologically-basedpharmacokinetic model. For example, as shown in FIGS. 32 through 35,physiological model accepter module 3464 may accept aphysiologically-based pharmacokinetic model. In one embodiment,physiological model accepter module 3464 may accept a pharmacokineticmodel based on weight and height. A pharmacokinetic model based onweight and height may present pharmacokinetic information based onphysiological attributes of an individual or a group of individuals. Forexample, a physiologically-based pharmacokinetic model may be derivedfrom a clinical trial by using the results only from a group ofindividuals meeting a specific weight and height requirement. Otherphysiologic attributes a pharmacokinetic model may be based from mayinclude age, gender, allergy information, and/or racial background.Accepting and/or utilizing a physiologically-based pharmacokinetic modelmay serve to more accurately determine a pharmacokinetic model for anindividual. In some instances, physiological model accepter module 3464may include a computer processor.

Further, operation 4706 illustrates accepting an in vitro-basedpharmacokinetic model. For example, as shown in FIGS. 32 through 35, invitro model accepter module 3466 may accept an in vitro-basedpharmacokinetic model. An in vitro-based pharmacokinetic model mayinclude a model derived from a controlled experiment outside of a livingorganism. One example of an in vitro experiment may include anexperiment in a test tube. In one embodiment, in vitro model acceptermodule 3466 may accept an in vitro-based pharmacokinetic model formorphine developed from a test tube experiment located in a researchlaboratory. One example of in vitro-based pharmacokinetic modelingsoftware may include DDDPlus, available from Simulations Plus, Inc.Another example of utilizing a physiologic-based simulation model atleast partially based on in vitro data may be found in Grass et al.,U.S. Pat. No. 6,647,358, which is incorporated herein by reference. Insome instances, in vitro model accepter module 3466 may include acomputer processor.

Further, operation 4708 illustrates accepting an output fromphysiologically-based pharmacokinetic modeling software. For example, asshown in FIGS. 32 through 35, software output accepter module 3468 mayaccept an output from physiologically-based pharmacokinetic modelingsoftware. In one embodiment, software output accepter module 3468 mayaccept an output from physiologically-based pharmacokinetic modelingsoftware. Accepting an output may include, for example, accepting adigital file with pharmacokinetic information and/or accepting printedinformation, such as a plasma drug concentration versus time grapheddepiction. Some examples of physiologically-based pharmacokineticmodeling software may include, for example, acslXtreme, GNU MCSim,PK-Sim, Simcyp, and/or GastroPlus. In some instances, software outputaccepter module 3468 may include a computer processor.

FIG. 48 illustrates alternative embodiments of the example operationalflow 4500 of FIG. 45. FIG. 48 illustrates example embodiments whereoperation 4510 may include at least one additional operation. Additionaloperations may include operation 4802.

Operation 4802 illustrates accepting pharmacokinetic profile informationfor a bioactive agent including at least one of an absorptioncharacterisitic, a distribution characteristic, a metabolizationcharacteristic, or an excretion characteristic. For example, as shown inFIGS. 32 through 35, characteristic accepter module 3470 may acceptpharmacokinetic profile information for a bioactive agent including atleast one of an absorption characterisitic, a distributioncharacteristic, a metabolization characteristic, or an excretioncharacteristic. An absorption characteristic may include a bioactiveagent route of administration, the rate of dissolution of a bioactiveagent, and/or ionization of a molecule. In one embodiment,characteristic accepter module 3470 may accept an absorptioncharacteristic including a rate of dissolution for a medication intablet form having an enteric coating. A distribution characteristic mayinclude permeability between tissues, blood flow and perfusion rate ofthe tissue, pH parturition, and/or ability of the drug to bind plasmaproteins and tissue. In one embodiment, characteristic accepter module3470 may accept a distribution characteristic for morphine, including avolume of distribution of 3 L/kg of body weight. A metabolizationcharacteristic may include, for example, a metabolic rate and mayinclude and/or be influenced by the presence of a second drug and/orcompound. Metabolization may include modification and/or degradation,for example, by an enzyme or enzyme complex. For example, metabolizationmay include modification of a first drug into a more active version ofthe first drug and/or a second drug. In one embodiment, characteristicaccepter module 3470 may accept a metabolic rate for morphine. Anexcretion characteristic may include an excretion rate, for exampleexpressed in ng/mL/min. In one embodiment, characteristic acceptermodule 3470 may accept an excretion characteristic for morphine and/ormorphine metabolites, such as 500 ng/mL/min. In some instances,characteristic accepter module 3470 may include a computer processor.

FIG. 49 illustrates alternative embodiments of the example operationalflow 4500 of FIG. 45. FIG. 49 illustrates example embodiments whereoperation 4510 may include at least one additional operation. Additionaloperations may include operation 4902, operation 4904, operation 4906,and/or operation 4908.

Operation 4902 illustrates accepting an indication of a pharmacokineticprofile at least partly based on at least one attribute of theindividual. For example, as shown in FIGS. 32 through 35, attributeprofile accepter module 3472 may accepting an indication of apharmacokinetic profile at least partly based on at least one attributeof the individual. In one embodiment, attribute profile accepter module3472 may accept an indication of a pharmacokinetic profile at leastpartly based on age and weight of an individual. Accepting an indicationof a pharmacokinetic profile at least partly based on an attribute ofthe individual may serve to more accurately predict the effects of abioactive agent on the individual by more closely matching theindividual's attributes with data from pharmaceutical tests involvingpeople similar to the individual. In some instances, attribute profileaccepter module 3472 may include a computer processor.

Further, operation 4904 illustrates accepting an indication of apharmacokinetic profile at least partly based on at least one of renalfailure, weight, hepatic failure, dehydration, sex, or age. For example,as shown in FIGS. 32 through 35, physiological characteristic acceptermodule 3474 may accept an indication of a pharmacokinetic profile atleast partly based on at least one of renal failure, obesity, hepaticfailure, dehydration, sex, or age. In one embodiment, physiologicalcharacteristic accepter module 3474 may accept an indication of apharmacokinetic profile at least partly based on obesity and age. Renalfailure may include a situation where at least one kidney fails toproperly function. Weight may include obesity, abnormal weight, and/orclinically underweight physiology, for example. Obesity may include asituation where body fat accumulates to a harmful degree. Obesity and/orabnormal weight characteristics may be measured and/or assessed using abody mass index. Hepatic failure may include a situation where the liveris unable to perform its normal metabolic and/or synthetic functions.Dehydration may include the absence and/or removal of water from thebody and may negatively affect a bioactive agent effect on anindividual. Additionally, sex and age may affect the magnitude of effectthe bioactive agent may have on an individual. For example, an elderlyperson may not be affected as greatly as a young person because of aslower metabolic rate. In some instances, physiological characteristicaccepter module 3474 may include a computer processor.

Further, operation 4906 illustrates accepting an indication of apharmacokinetic profile at least partially based on a medical history.For example, as shown in FIGS. 32 through 35, medical history profileaccepter module 3476 may accept an indication of a pharmacokineticprofile at least partially based on a personal medical history. Apersonal medical history may include a list of previous illnesses,symptoms, medicines, treatments, health risk factors, operations, and/ordoctor visits associated with at least one individual. In oneembodiment, medical history profile accepter module 3476 may accept anindication of an individualized pharmacokinetic profile based onpreviously prescribed medications for an individual. An individualizedpharmacokinetic profile may serve to more closely tailor a bioactiveagent to the therapeutic needs of the individual. For example, anindividualized pharmacokinetic profile may take into account absorptionrates for a certain family of bioactive agents, such as opioids. If theindividual reacts to a first opioid, in a certain way, the individualmay react to a second opioid in a similar way. In some instances,medical history profile accepter module 3476 may include a computerprocessor.

Further, operation 4908 illustrates accepting an indication of apharmacokinetic profile at least partially based on at least oneattribute of a group of people. For example, as shown in FIGS. 32through 35, group attribute accepter module 3478 may accept anindication of a pharmacokinetic profile at least partially based on atleast one attribute of a group of people. In one embodiment, groupattribute accepter module 3478 may accept an indication of apharmacokinetic profile based on the weight of a group of people wherethe group of people may be similar in weight to the individual.Utilizing a pharmacokinetic profile based on a group of people with atleast one similar attribute to the individual may serve to betterpredict how a bioactive agent may affect the individual. In someinstances, group attribute accepter module 3478 may include a computerprocessor.

FIG. 50 illustrates alternative embodiments of the example operationalflow 4500 of FIG. 45. FIG. 50 illustrates example embodiments whereoperation 4510 may include at least one additional operation. Additionaloperations may include operation 5002.

Operation 5002 illustrates accepting at least one of a Tmin, Tmax, Cmin,or a Cmax value for the bioactive agent. For example, as shown in FIGS.32 through 35, parameter accepter module 3480 may accept at least one ofa Tmin, Tmax, Cmin, or a Cmax value for the bioactive agent. A Tminvalue may include a time when a bioactive agent plasma concentration isat a minimum value. A Tmax value may include a time when a bioactiveagent plasma concentration is at a maximum value. A Cmin value mayinclude a minimum bioactive agent concentration value. A Cmax value mayinclude a maximum bioactive agent concentration value. In oneembodiment, parameter accepter module 3480 may accept a Tmin and a Tmaxvalue. Accepting a Tmin and a Tmax value for a bioactive agent during abioactive agent regimen may serve to help determine an appropriate timeto administer a corresponding artificial sensory experience. Anappropriate time to administer a corresponding artificial sensoryexperience may include a time period when a bioactive agent is at a lowand/or minimum concentration. An artificial sensory experience maycompensate for a low and/or minimum bioactive agent concentration byserving as a distraction. In some instances, parameter accepter module3480 may include a computer processor.

FIG. 51 illustrates an operational flow 5100 representing exampleoperations related to accepting an indication of at least one of apharmacokinetic or pharmacodynamic profile of a bioactive agent and anindication of a schedule for administration of the bioactive agent to anindividual and/or presenting an indication of an artificial sensoryexperience at least partly based on the accepting an indication of theat least one of a pharmacokinetic or pharmacodynamic profile of thebioactive agent and the indication of the schedule for administration ofthe bioactive agent to the individual. In FIG. 51 and in followingfigures that include various examples of operational flows, discussionand explanation may be provided with respect to the above-describedexamples of FIGS. 32 through 35, and/or with respect to other examplesand contexts. However, it should be understood that the operationalflows may be executed in a number of other environments and contexts,and/or in modified versions of FIGS. 32 through 35. Also, although thevarious operational flows are presented in the sequence(s) illustrated,it should be understood that the various operations may be performed inother orders than those which are illustrated, or may be performedconcurrently.

After a start operation, the operational flow 5100 moves to operation5110. Operation 5110 depicts accepting an indication of at least one ofa pharmacokinetic or pharmacodynamic profile of a bioactive agent and anindication of a schedule for administration of the bioactive agent to anindividual. For example, as shown in FIGS. 32 through 35, acceptermodule 3402 may accept an indication of at least one of apharmacokinetic or pharmacodynamic profile of a bioactive agent and anindication of a schedule for administration of the bioactive agent to anindividual. In one embodiment, accepter module 3402 may accept anindication of a pharmacokinetic profile for an opioid and a schedule foran intravenous administration of the opioid to an individual. In thisembodiment, the schedule may include specific times and/or methods thatthe bioactive agent may be administered. For example, a time schedulemay specify that an individual should receive a specific dose ofmorphine every two hours. In another example, an administration schedulemay specify that an opioid should be administered intravenously at nightand orally during waking hours. In some instances, accepter module 3402may include a computer processor and/or a user interface coupled to thecomputer processor.

Then, operation 5120 depicts presenting an indication of an artificialsensory experience at least partly based on the accepting an indicationof the at least one of a pharmacokinetic or pharmacodynamic profile ofthe bioactive agent and the indication of the schedule foradministration of the bioactive agent to the individual. For example, asshown in FIGS. 32 through 35, presenter module 3410 may present anindication of an artificial sensory experience at least partly based onthe accepting an indication of the at least one of a pharmacokinetic orpharmacodynamic profile of the bioactive agent and the indication of theschedule for administration of the bioactive agent to the individual. Inone embodiment, presenter module 3410 may present an indication of avirtual world configured for distracting an individual at least partlybased on accepting an indication of a pharmacokinetic profile formorphine and an administration time schedule. In this embodiment, thebioactive administration schedule may be coordinated so that anartificial sensory experience is administered when the morphine may beless effective. Coordinating an artificial sensory experienceadministration schedule may serve to more efficiently distract and/orreduce, for example, an individual's pain during a period of lowbioactive agent concentration in an individual's blood. In someinstances, presenter module 3410 may include a computer processor, adisplay, and/or a printer.

FIG. 52 illustrates an operational flow 5200 representing exampleoperations related to accepting an indication of a bioactive agentadministration for an individual, determining at least one of apharmacokinetic or pharmacodynamic profile of the bioactive agent,and/or presenting an indication of an artificial sensory experience atleast partly based on the accepting an indication of the at least one ofa pharmacokinetic or pharmacodynamic profile of the bioactive agent andthe indication of the schedule for administration of the bioactive agentto the individual. In FIG. 52 and in following figures that includevarious examples of operational flows, discussion and explanation may beprovided with respect to the above-described examples of FIGS. 32through 35, and/or with respect to other examples and contexts. However,it should be understood that the operational flows may be executed in anumber of other environments and contexts, and/or in modified versionsof FIGS. 32 through 35. Also, although the various operational flows arepresented in the sequence(s) illustrated, it should be understood thatthe various operations may be performed in other orders than those whichare illustrated, or may be performed concurrently.

After a start operation, the operational flow 5200 moves to operation5210. Operation 5210 depicts accepting an indication of a bioactiveagent administration for an individual. For example, as shown in FIGS.32 through 35, accepter module 3402 may accept an indication of abioactive agent administration for an individual. In one embodiment,accepter module 3402 may accept an indication of an administration of ananalgesic, such as naproxen. Accepting an indication of anadministration of a bioactive agent may include, for example, acceptingan administration schedule, accepting a delivery method, and/oraccepting a bioactive agent type. In some instances, accepter module3402 may include a computer processor and/or a user interface coupled tothe computer processor.

Then, operation 5220 depicts determining at least one of apharmacokinetic or pharmacodynamic profile of the bioactive agent. Forexample, as shown in FIGS. 32 through 35, determiner module 3482 maydetermine at least one of a pharmacokinetic or pharmacodynamic profileof the bioactive agent. In one embodiment, determiner module 3482 maydetermine at least one of a pharmacokinetic profile of an analgesic,such as naproxen. Determining at least one of a pharmacokinetic orpharmacodynamic profile for a bioactive agent may include using amedical history, such as a personal medical history including personalmedication efficacy and/or individual attributes (gender, weight,height, etc.). Additionally, determiner module 3482 may determine apharmacokinetic and/or pharmacodynamic profile for a bioactive agent bycomparing an individual's characteristics with predetermined compatablepharmacokinetic and/or pharmacodynamic profiles, for example from adatabase. In some instances, determiner module 3482 may include acomputer processor.

Then, operation 5220 depicts presenting an indication of an artificialsensory experience at least partly based on the accepting an indicationof the at least one of a pharmacokinetic or pharmacodynamic profile ofthe bioactive agent and the indication of the schedule foradministration of the bioactive agent to the individual. For example, asshown in FIGS. 32 through 35, presenter module 3410 may present anindication of an artificial sensory experience at least partly based onthe accepting an indication of the at least one of a pharmacokinetic orpharmacodynamic profile of the bioactive agent and the indication of theschedule for administration of the bioactive agent to the individual. Inone embodiment, presenter module 3410 may present to a computer monitoran indication of a virtual world based on accepting an indication of apharmacokinetic profile for naproxen and an indication of anadministration schedule for the naproxen. The indication of theartificial sensory experience may be presented, for example, bydisplaying the indication on a display device, such as a computermonitor, a mobile device, such as a Blackberry device, and/or a printerdevice, such as a printed piece of paper from a laser printer. In someinstances, presenter module 3410 may include a computer processor and/ora display device, such as a computer monitor and/or a printer.

FIG. 53 illustrates an operational flow 5300 representing exampleoperations related to accepting an indication of at least one bioactiveagent and an indication of a schedule for administration of thebioactive agent to an individual and/or presenting an indication of anartificial sensory experience at least partly based on at least one of apharmacokinetic profile or pharmacodynamic profile of the bioactiveagent and the indication of the schedule for administration of thebioactive agent to the individual. In FIG. 53 and in following figuresthat include various examples of operational flows, discussion andexplanation may be provided with respect to the above-described examplesof FIGS. 32 through 35, and/or with respect to other examples andcontexts. However, it should be understood that the operational flowsmay be executed in a number of other environments and contexts, and/orin modified versions of FIGS. 32 through 35. Also, although the variousoperational flows are presented in the sequence(s) illustrated, itshould be understood that the various operations may be performed inother orders than those which are illustrated, or may be performedconcurrently.

After a start operation, the operational flow 5300 moves to operation5310. Operation 5310 depicts accepting an indication of at least onebioactive agent and an indication of a schedule for administration ofthe bioactive agent to an individual. For example, as shown in FIGS. 32through 35, accepter module 3402 may accept an indication of at leastone bioactive agent and an indication of a schedule for administrationof the bioactive agent to an individual. In one embodiment, acceptermodule 3402 may accept an indication of an analgesic, such as ibuprofen,and accept an indication of an administration of the ibuprofen.Accepting an indication of a bioactive agent may include, for example,accepting an indication of a prescription medication from a health careprovider. Additionally, an indication of a bioactive agent may beaccepted from a computer database. Accepting an indication of abioactive agent administration schedule may include specific timesand/or methods that the bioactive agent may be administered.Additionally, a bioactive agent administration schedule may includereceiving a dose with or without food, which may be specific food,and/or together with or separate from other drugs. For example, a timeschedule may specify that an individual should receive a specific doseof ibuprofen every two hours. In another example, an administrationschedule may specify that an analgesic should be administeredintravenously at night and orally during waking hours. Accepting anindication of an administration schedule may include accepting adelivery method and/or accepting a bioactive agent to be administered.In some instances, accepter module 3402 may include a computer processorand/or a user interface coupled to the computer processor.

Then, operation 5320 depicts presenting an indication of an artificialsensory experience at least partly based on the accepting an indicationof the at least one of a pharmacokinetic or pharmacodynamic profile ofthe bioactive agent and the indication of the schedule foradministration of the bioactive agent to the individual. For example, asshown in FIGS. 32 through 35, presenter module 3410 may present anindication of an artificial sensory experience at least partly based onthe accepting an indication of the at least one of a pharmacokinetic orpharmacodynamic profile of the bioactive agent and the indication of theschedule for administration of the bioactive agent to the individual. Inone embodiment, presenter module 3410 may present to a computer monitoran indication of a virtual world based on accepting an indication of apharmacokinetic profile for ibuprofen and an indication of anadministration schedule for the ibuprofen. The indication of theartificial sensory experience may be presented, for example, bydisplaying the indication on a display device, such as a computermonitor, a mobile device, such as a Blackberry device, and/or a printerdevice, such as a printed piece of paper from a laser printer. In someinstances, presenter module 3410 may include a computer processor and/ora display device, such as a computer monitor and/or a printer.

FIG. 54 illustrates a partial view of an example computer programproduct 5400 that includes a computer program 5404 for executing acomputer process on a computing device. An embodiment of the examplecomputer program product 5400 is provided using a signal-bearing mediumbearing 5402, and may include one or more instructions for accepting anindication of a schedule for administration of a bioactive agent to anindividual and one or more instructions for presenting an indication oftan artificial sensory experience at least partly based on the acceptingan indication of the schedule for administration of the bioactive agentto the individual. The one or more instructions may be, for example,computer executable and/or logic-implemented instructions. In oneimplementation, the signal-bearing medium 5402 may include acomputer-readable medium 5406. In one implementation, the signal bearingmedium 5402 may include a recordable medium 5408. In one implementation,the signal bearing medium 5402 may include a communications medium 5410.

FIG. 55 illustrates an example system 5500 in which embodiments may beimplemented. The system 5500 includes a computing system environment.The system 5500 also illustrates the user 118 using a device 5504, whichis optionally shown as being in communication with a computing device5502 by way of an optional coupling 5506. The optional coupling 5506 mayrepresent a local, wide-area, or peer-to-peer network, or may representa bus that is internal to a computing device (e.g., in exampleembodiments in which the computing device 5502 is contained in whole orin part within the device 5504). A storage medium 5508 may be anycomputer storage media.

The computing device 5502 includes computer-executable instructions 5510that when executed on the computing device 5502 cause the computingdevice 5502 to accept an indication of a schedule for administration ofa bioactive agent to an individual and present an indication of anartificial sensory experience at least partly based on the accepting anindication of the schedule for administration of the bioactive agent tothe individual. As referenced above and as shown in FIG. 55, in someexamples, the computing device 5502 may optionally be contained in wholeor in part within the device 5504.

In FIG. 55, then, the system 5500 includes at least one computing device(e.g., 5502 and/or 5504). The computer-executable instructions 5510 maybe executed on one or more of the at least one computing device. Forexample, the computing device 5502 may implement the computer-executableinstructions 5510 and output a result to (and/or receive data from) thecomputing device 5504. Since the computing device 5502 may be wholly orpartially contained within the computing device 5504, the device 5504also may be said to execute some or all of the computer-executableinstructions 5510, in order to be caused to perform or implement, forexample, various ones of the techniques described herein, or othertechniques.

The device 5504 may include, for example, a portable computing device,workstation, or desktop computing device. In another example embodiment,the computing device 5502 is operable to communicate with the device5504 associated with the user 118 to receive information about the inputfrom the user 118 for performing data access and data processing andpresenting an output of the user-health test function at least partlybased on the user data.

Although a user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that a user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents). In addition, a user 118, asset forth herein, although shown as a single entity may in fact becomposed of two or more entities. Those skilled in the art willappreciate that, in general, the same may be said of “sender” and/orother entity-oriented terms as such terms are used herein.

Following are a series of flowcharts depicting implementations. For easeof understanding, the flowcharts are organized such that the initialflowcharts present implementations via an example implementation andthereafter the following flowcharts present alternate implementationsand/or expansions of the initial flowchart(s) as either sub-componentoperations or additional component operations building on one or moreearlier-presented flowcharts. Those having skill in the art willappreciate that the style of presentation utilized herein (e.g.,beginning with a presentation of a flowchart(s) presenting an exampleimplementation and thereafter providing additions to and/or furtherdetails in subsequent flowcharts) generally allows for a rapid and easyunderstanding of the various process implementations. In addition, thoseskilled in the art will further appreciate that the style ofpresentation used herein also lends itself well to modular and/orobject-oriented program design paradigms.

Those skilled in the art will appreciate that the foregoing specificexemplary processes and/or devices and/or technologies arerepresentative of more general processes and/or devices and/ortechnologies taught elsewhere herein, such as in the claims filedherewith and/or elsewhere in the present application.

Those having skill in the art will recognize that the state of the arthas progressed to the point where there is little distinction leftbetween hardware, software, and/or firmware implementations of aspectsof systems; the use of hardware, software, and/or firmware is generally(but not always, in that in certain contexts the choice between hardwareand software can become significant) a design choice representing costvs. efficiency tradeoffs. Those having skill in the art will appreciatethat there are various vehicles by which processes and/or systems and/orother technologies described herein can be effected (e.g., hardware,software, and/or firmware), and that the preferred vehicle will varywith the context in which the processes and/or systems and/or othertechnologies are deployed. For example, if an implementer determinesthat speed and accuracy are paramount, the implementer may opt for amainly hardware and/or firmware vehicle; alternatively, if flexibilityis paramount, the implementer may opt for a mainly softwareimplementation; or, yet again alternatively, the implementer may opt forsome combination of hardware, software, and/or firmware. Hence, thereare several possible vehicles by which the processes and/or devicesand/or other technologies described herein may be effected, none ofwhich is inherently superior to the other in that any vehicle to beutilized is a choice dependent upon the context in which the vehiclewill be deployed and the specific concerns (e.g., speed, flexibility, orpredictability) of the implementer, any of which may vary. Those skilledin the art will recognize that optical aspects of implementations willtypically employ optically-oriented hardware, software, and or firmware.

In some implementations described herein, logic and similarimplementations may include software or other control structuressuitable to operation. Electronic circuitry, for example, may manifestone or more paths of electrical current constructed and arranged toimplement various logic functions as described herein. In someimplementations, one or more media are configured to bear adevice-detectable implementation if such media hold or transmit aspecial-purpose device instruction set operable to perform as describedherein. In some variants, for example, this may manifest as an update orother modification of existing software or firmware, or of gate arraysor other programmable hardware, such as by performing a reception of ora transmission of one or more instructions in relation to one or moreoperations described herein. Alternatively or additionally, in somevariants, an implementation may include special-purpose hardware,software, firmware components, and/or general-purpose componentsexecuting or otherwise invoking special-purpose components.Specifications or other implementations may be transmitted by one ormore instances of tangible transmission media as described herein,optionally by packet transmission or otherwise by passing throughdistributed media at various times.

Alternatively or additionally, implementations may include executing aspecial-purpose instruction sequence or otherwise invoking circuitry forenabling, triggering, coordinating, requesting, or otherwise causing oneor more occurrences of any functional operations described above. Insome variants, operational or other logical descriptions herein may beexpressed directly as source code and compiled or otherwise invoked asan executable instruction sequence. In some contexts, for example, C++or other code sequences can be compiled directly or otherwiseimplemented in high-level descriptor languages (e.g., alogic-synthesizable language, a hardware description language, ahardware design simulation, and/or other such similar mode(s) ofexpression). Alternatively or additionally, some or all of the logicalexpression may be manifested as a Verilog-type hardware description orother circuitry model before physical implementation in hardware,especially for basic operations or timing-critical applications. Thoseskilled in the art will recognize how to obtain, configure, and optimizesuitable transmission or computational elements, material supplies,actuators, or other common structures in light of these teachings.

The foregoing detailed description has set forth various embodiments ofthe devices and/or processes via the use of block diagrams, flowcharts,and/or examples. Insofar as such block diagrams, flowcharts, and/orexamples contain one or more functions and/or operations, it will beunderstood by those within the art that each function and/or operationwithin such block diagrams, flowcharts, or examples can be implemented,individually and/or collectively, by a wide range of hardware, software,firmware, or virtually any combination thereof. In one embodiment,several portions of the subject matter described herein may beimplemented via Application Specific Integrated Circuits (ASICs), FieldProgrammable Gate Arrays (FPGAs), digital signal processors (DSPs), orother integrated formats. However, those skilled in the art willrecognize that some aspects of the embodiments disclosed herein, inwhole or in part, can be equivalently implemented in integratedcircuits, as one or more computer programs running on one or morecomputers (e.g., as one or more programs running on one or more computersystems), as one or more programs running on one or more processors(e.g., as one or more programs running on one or more microprocessors),as firmware, or as virtually any combination thereof, and that designingthe circuitry and/or writing the code for the software and or firmwarewould be well within the skill of one of skill in the art in light ofthis disclosure. In addition, those skilled in the art will appreciatethat the mechanisms of the subject matter described herein are capableof being distributed as a program product in a variety of forms, andthat an illustrative embodiment of the subject matter described hereinapplies regardless of the particular type of signal bearing medium usedto actually carry out the distribution. Examples of a signal bearingmedium include, but are not limited to, the following: a recordable typemedium such as a floppy disk, a hard disk drive, a Compact Disc (CD), aDigital Video Disk (DVD), a digital tape, a computer memory, etc.; and atransmission type medium such as a digital and/or an analogcommunication medium (e.g., a fiber optic cable, a waveguide, a wiredcommunications link, a wireless communication link (e.g., transmitter,receiver, transmission logic, reception logic, etc.), etc.).

In a general sense, those skilled in the art will recognize that thevarious embodiments described herein can be implemented, individuallyand/or collectively, by various types of electro-mechanical systemshaving a wide range of electrical components such as hardware, software,firmware, and/or virtually any combination thereof; and a wide range ofcomponents that may impart mechanical force or motion such as rigidbodies, spring or torsional bodies, hydraulics, electro-magneticallyactuated devices, and/or virtually any combination thereof.Consequently, as used herein “electro-mechanical system” includes, butis not limited to, electrical circuitry operably coupled with atransducer (e.g., an actuator, a motor, a piezoelectric crystal, a MicroElectro Mechanical System (MEMS), etc.), electrical circuitry having atleast one discrete electrical circuit, electrical circuitry having atleast one integrated circuit, electrical circuitry having at least oneapplication specific integrated circuit, electrical circuitry forming ageneral purpose computing device configured by a computer program (e.g.,a general purpose computer configured by a computer program which atleast partially carries out processes and/or devices described herein,or a microprocessor configured by a computer program which at leastpartially carries out processes and/or devices described herein),electrical circuitry forming a memory device (e.g., forms of memory(e.g., random access, flash, read only, etc.)), electrical circuitryforming a communications device (e.g., a modem, communications switch,optical-electrical equipment, etc.), and/or any non-electrical analogthereto, such as optical or other analogs. Those skilled in the art willalso appreciate that examples of electromechanical systems include butare not limited to a variety of consumer electronics systems, medicaldevices, as well as other systems such as motorized transport systems,factory automation systems, security systems, and/orcommunication/computing systems. Those skilled in the art will recognizethat electromechanical as used herein is not necessarily limited to asystem that has both electrical and mechanical actuation except ascontext may dictate otherwise.

In a general sense, those skilled in the art will recognize that thevarious aspects described herein which can be implemented, individuallyand/or collectively, by a wide range of hardware, software, firmware,and/or any combination thereof can be viewed as being composed ofvarious types of “electrical circuitry.” Consequently, as used herein“electrical circuitry” includes, but is not limited to, electricalcircuitry having at least one discrete electrical circuit, electricalcircuitry having at least one integrated circuit, electrical circuitryhaving at least one application specific integrated circuit, electricalcircuitry forming a general purpose computing device configured by acomputer program (e.g., a general purpose computer configured by acomputer program which at least partially carries out processes and/ordevices described herein, or a microprocessor configured by a computerprogram which at least partially carries out processes and/or devicesdescribed herein), electrical circuitry forming a memory device (e.g.,forms of memory (e.g., random access, flash, read only, etc.)), and/orelectrical circuitry forming a communications device (e.g., a modem,communications switch, optical-electrical equipment, etc.). Those havingskill in the art will recognize that the subject matter described hereinmay be implemented in an analog or digital fashion or some combinationthereof.

Those skilled in the art will recognize that at least a portion of thedevices and/or processes described herein can be integrated into a dataprocessing system. Those having skill in the art will recognize that adata processing system generally includes one or more of a system unithousing, a video display device, memory such as volatile or non-volatilememory, processors such as microprocessors or digital signal processors,computational entities such as operating systems, drivers, graphicaluser interfaces, and applications programs, one or more interactiondevices (e.g., a touch pad, a touch screen, an antenna, etc.), and/orcontrol systems including feedback loops and control motors (e.g.,feedback for sensing position and/or velocity; control motors for movingand/or adjusting components and/or quantities). A data processing systemmay be implemented utilizing suitable commercially available components,such as those typically found in data computing/communication and/ornetwork computing/communication systems.

Those skilled in the art will recognize that it is common within the artto implement devices and/or processes and/or systems, and thereafter useengineering and/or other practices to integrate such implemented devicesand/or processes and/or systems into more comprehensive devices and/orprocesses and/or systems. That is, at least a portion of the devicesand/or processes and/or systems described herein can be integrated intoother devices and/or processes and/or systems via a reasonable amount ofexperimentation. Those having skill in the art will recognize thatexamples of such other devices and/or processes and/or systems mightinclude—as appropriate to context and application—all or part of devicesand/or processes and/or systems of (a) an air conveyance (e.g., anairplane, rocket, helicopter, etc.), (b) a ground conveyance (e.g., acar, truck, locomotive, tank, armored personnel carrier, etc.), (c) abuilding (e.g., a home, warehouse, office, etc.), (d) an appliance(e.g., a refrigerator, a washing machine, a dryer, etc.), (e) acommunications system (e.g., a networked system, a telephone system, aVoice over IP system, etc.), (f) a business entity (e.g., an InternetService Provider (ISP) entity such as Comcast Cable, Qwest, SouthwesternBell, etc.), or (g) a wired/wireless services entity (e.g., Sprint,Cingular, Nextel, etc.), etc.

In certain cases, use of a system or method may occur in a territoryeven if components are located outside the territory. For example, in adistributed computing context, use of a distributed computing system mayoccur in a territory even though parts of the system may be locatedoutside of the territory (e.g., relay, server, processor, signal-bearingmedium, transmitting computer, receiving computer, etc. located outsidethe territory).

A sale of a system or method may likewise occur in a territory even ifcomponents of the system or method are located and/or used outside theterritory.

Further, implementation of at least part of a system for performing amethod in one territory does not preclude use of the system in anotherterritory.

All of the above U.S. patents, U.S. patent application publications,U.S. patent applications, foreign patents, foreign patent applicationsand non-patent publications referred to in this specification and/orlisted in any Application Data Sheet, are incorporated herein byreference, to the extent not inconsistent herewith.

One skilled in the art will recognize that the herein describedcomponents (e.g., operations), devices, objects, and the discussionaccompanying them are used as examples for the sake of conceptualclarity and that various configuration modifications are contemplated.Consequently, as used herein, the specific exemplars set forth and theaccompanying discussion are intended to be representative of their moregeneral classes. In general, use of any specific exemplar is intended tobe representative of its class, and the non-inclusion of specificcomponents (e.g., operations), devices, and objects should not be takenlimiting.

Although user 118 is shown/described herein as a single illustratedfigure, those skilled in the art will appreciate that user 118 may berepresentative of a human user, a robotic user (e.g., computationalentity), and/or substantially any combination thereof (e.g., a user maybe assisted by one or more robotic agents) unless context dictatesotherwise. Those skilled in the art will appreciate that, in general,the same may be said of “sender” and/or other entity-oriented terms assuch terms are used herein unless context dictates otherwise.

With respect to the use of substantially any plural and/or singularterms herein, those having skill in the art can translate from theplural to the singular and/or from the singular to the plural as isappropriate to the context and/or application. The varioussingular/plural permutations are not expressly set forth herein for sakeof clarity.

The herein described subject matter sometimes illustrates differentcomponents contained within, or connected with, different othercomponents. It is to be understood that such depicted architectures aremerely exemplary, and that in fact many other architectures may beimplemented which achieve the same functionality. In a conceptual sense,any arrangement of components to achieve the same functionality iseffectively “associated” such that the desired functionality isachieved. Hence, any two components herein combined to achieve aparticular functionality can be seen as “associated with” each othersuch that the desired functionality is achieved, irrespective ofarchitectures or intermedial components. Likewise, any two components soassociated can also be viewed as being “operably connected”, or“operably coupled,” to each other to achieve the desired functionality,and any two components capable of being so associated can also be viewedas being “operably couplable,” to each other to achieve the desiredfunctionality. Specific examples of operably couplable include but arenot limited to physically mateable and/or physically interactingcomponents, and/or wirelessly interactable, and/or wirelesslyinteracting components, and/or logically interacting, and/or logicallyinteractable components.

In some instances, one or more components may be referred to herein as“configured to,” “configurable to,” “operable/operative to,”“adapted/adaptable,” “able to,” “conformable/conformed to,” etc. Thoseskilled in the art will recognize that “configured to” can generallyencompass active-state components and/or inactive-state componentsand/or standby-state components, unless context requires otherwise.

While particular aspects of the present subject matter described hereinhave been shown and described, it will be apparent to those skilled inthe art that, based upon the teachings herein, changes and modificationsmay be made without departing from the subject matter described hereinand its broader aspects and, therefore, the appended claims are toencompass within their scope all such changes and modifications as arewithin the true spirit and scope of the subject matter described herein.It will be understood by those within the art that, in general, termsused herein, and especially in the appended claims (e.g., bodies of theappended claims) are generally intended as “open” terms (e.g., the term“including” should be interpreted as “including but not limited to,” theterm “having” should be interpreted as “having at least,” the term“includes” should be interpreted as “includes but is not limited to,”etc.). It will be further understood by those within the art that if aspecific number of an introduced claim recitation is intended, such anintent will be explicitly recited in the claim, and in the absence ofsuch recitation no such intent is present. For example, as an aid tounderstanding, the following appended claims may contain usage of theintroductory phrases “at least one” and “one or more” to introduce claimrecitations. However, the use of such phrases should not be construed toimply that the introduction of a claim recitation by the indefinitearticles “a” or “an” limits any particular claim containing suchintroduced claim recitation to claims containing only one suchrecitation, even when the same claim includes the introductory phrases“one or more” or “at least one” and indefinite articles such as “a” or“an” (e.g., “a” and/or “an” should typically be interpreted to mean “atleast one” or “one or more”); the same holds true for the use ofdefinite articles used to introduce claim recitations. In addition, evenif a specific number of an introduced claim recitation is explicitlyrecited, those skilled in the art will recognize that such recitationshould typically be interpreted to mean at least the recited number(e.g., the bare recitation of “two recitations,” without othermodifiers, typically means at least two recitations, or two or morerecitations). Furthermore, in those instances where a conventionanalogous to “at least one of A, B, and C, etc.” is used, in generalsuch a construction is intended in the sense one having skill in the artwould understand the convention (e.g., “a system having at least one ofA, B, and C” would include but not be limited to systems that have Aalone, B alone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). In those instances where aconvention analogous to “at least one of A, B, or C, etc.” is used, ingeneral such a construction is intended in the sense one having skill inthe art would understand the convention (e.g., “a system having at leastone of A, B, or C” would include but not be limited to systems that haveA alone, B alone, C alone, A and B together, A and C together, B and Ctogether, and/or A, B, and C together, etc.). It will be furtherunderstood by those within the art that typically a disjunctive wordand/or phrase presenting two or more alternative terms, whether in thedescription, claims, or drawings, should be understood to contemplatethe possibilities of including one of the terms, either of the terms, orboth terms unless context dictates otherwise. For example, the phrase “Aor B” will be typically understood to include the possibilities of “A”or “B” or “A and B.”

With respect to the appended claims, those skilled in the art willappreciate that recited operations therein may generally be performed inany order. Also, although various operational flows are presented in asequence(s), it should be understood that the various operations may beperformed in other orders than those which are illustrated, or may beperformed concurrently. Examples of such alternate orderings may includeoverlapping, interleaved, interrupted, reordered, incremental,preparatory, supplemental, simultaneous, reverse, or other variantorderings, unless context dictates otherwise. Furthermore, terms like“responsive to,” “related to,” or other past-tense adjectives aregenerally not intended to exclude such variants, unless context dictatesotherwise.

White various aspects and embodiments have been disclosed herein, otheraspects and embodiments will be apparent to those skilled in the art.The various aspects and embodiments disclosed herein are for purposes ofillustration and are not intended to be limiting, with the true scopeand spirit being indicated by the following claims.

What is claimed is:
 1. A computer-implemented method, comprising:accepting a pharmacokinetic profile of a prescribed bioactive agent;accepting, using a suitable microprocessor, an indication of aprescribed schedule for administration of the prescribed bioactive agentto an individual; and presenting a prescription for engagement of theindividual with a virtual experience at at least one time when aconcentration of the prescribed bioactive agent is expected to be belowa substantially effective level at least partly based on accepting thepharmacokinetic profile of the prescribed bioactive agent and at leastpartially based on accepting the indication of the prescribed schedulefor administration of the prescribed bioactive agent to the individual,the pharmacokinetic profile of the prescribed bioactive agent includingat least one or more effective concentration levels of the prescribedbioactive agent.
 2. A system, comprising: means for accepting apharmacokinetic profile of a prescribed bioactive agent; means foraccepting an indication of a prescribed schedule for administration ofthe prescribed bioactive agent to an individual; and means forpresenting a prescription for engagement of the individual with avirtual experience at at least one time when a concentration of theprescribed bioactive agent is expected to be below a substantiallyeffective level at least partly based on accepting the pharmacokineticprofile of the prescribed bioactive agent and at least partially basedon accepting the indication of the prescribed schedule foradministration of the prescribed bioactive agent to the individual, thepharmacokinetic profile of the prescribed bioactive agent including atleast one or more effective concentration levels of the prescribedbioactive agent.
 3. The system of claim 2, wherein the means foraccepting an indication of a prescribed schedule for administration ofthe prescribed bioactive agent to an individual comprises: means foraccepting a bioactive agent time schedule.
 4. The system of claim 2,wherein the means for accepting an indication of a prescribed schedulefor administration of the prescribed bioactive agent to an individualcomprises: means for accepting at least one of a bioactive agentdelivery type or bioactive agent delivery dosage administrationschedule.
 5. The system of claim 2, wherein the means for accepting anindication of a prescribed schedule for administration of the prescribedbioactive agent to an individual comprises: means for accepting abioactive agent loading dose.
 6. The system of claim 2, furthercomprising: means for accepting an indication of at least one of apharmacokinetic or pharmacodynamic profile of a bioactive agent.
 7. Thesystem of claim 6, wherein the means for accepting an indication of atleast one of a pharmacokinetic or pharmacodynamic profile of a bioactiveagent comprises: means for accepting an indication of a time versusconcentration representation for a bioactive agent.
 8. The system ofclaim 6, wherein the means for accepting an indication of at least oneof a pharmacokinetic or pharmacodynamic profile of a bioactive agentcomprises: means for accepting an indication of a dose versus responserepresentation for a bioactive agent.
 9. The system of claim 6, whereinthe means for accepting an indication of at least one of apharmacokinetic or pharmacodynamic profile of a bioactive agentcomprises: means for accepting a pharmacokinetic model.
 10. The systemof claim 9, wherein the means for accepting a pharmacokinetic modelcomprises: means for accepting a physiologically-based pharmacokineticmodel.
 11. The system of claim 9, wherein the means for accepting apharmacokinetic model comprises: means for accepting an output fromphysiologically-based pharmacokinetic modeling software.
 12. The systemof claim 6, wherein the means for accepting an indication of at leastone of a pharmacokinetic or pharmacodynamic profile of a bioactive agentcomprises: means for accepting pharmacokinetic profile information for abioactive agent including at least one of an absorption characteristic,a distribution characteristic, a metabolization characteristic, or anexcretion characteristic.
 13. The system of claim 6, wherein the meansfor accepting an indication of at least one of a pharmacokinetic orpharmacodynamic profile of a bioactive agent comprises: means foraccepting an indication of a pharmacokinetic profile at least partlybased on at least one attribute of the individual.
 14. The system ofclaim 6, wherein the means for accepting an indication of at least oneof a pharmacokinetic or pharmacodynamic profile of a bioactive agentcomprises: means for accepting at least one of a Tmin, Tmax, Cmin, or aCmax value for the bioactive agent.
 15. The system of claim 2, whereinthe means for presenting a prescription for engagement of the individualwith a virtual experience comprises: means for presenting an indicationof a prescribed virtual experience.
 16. The system of claim 2, whereinthe means for presenting a prescription for engagement of the individualwith a virtual experience comprises: means for utilizing an algorithmfor recommending at least one virtual experience.
 17. The system ofclaim 16, wherein the means for utilizing an algorithm for recommendingat least one virtual experience comprises: means for utilizingpharmacokinetic modeling software.
 18. The system of claim 16, whereinthe means for utilizing an algorithm for recommending at least onevirtual experience comprises: means for utilizing pharmacodynamicmodeling software.
 19. The system of claim 16, wherein the means forutilizing an algorithm for recommending at least one virtual experiencecomprises: means for utilizing an algorithm configured for identifying acontraindication of the virtual experience.
 20. The system of claim 2,wherein the means for presenting a prescription for engagement of theindividual with a virtual experience comprises: means for presenting theprescription for engagement of the individual with the virtualexperience at least partly based on a personal medical history.
 21. Thesystem of claim 2, wherein the means for presenting a prescription forengagement of the individual with a virtual experience comprises: meansfor presenting the prescription of the individual with the virtualexperience at least partly based on experimental data.
 22. The system ofclaim 2, wherein the means for presenting a prescription for engagementof the individual with a virtual experience comprises: means forpresenting the prescription for engagement of the individual with thevirtual experience at least partly based on a medical reference tool.23. The system of claim 2, wherein the means for presenting aprescription for engagement of the individual with a virtual experiencecomprises: means for presenting the prescription for engagement of theindividual with the virtual experience to at least one output device.24. The system of claim 2, wherein the means for presenting aprescription for engagement of the individual with a virtual experiencecomprises: means for presenting the prescription for engagement of theindividual with the virtual experience to a third party.
 25. The systemof claim 24, wherein the means for presenting the prescription forengagement of the individual with the virtual experience to a thirdparty comprises: means for presenting the prescription for engagement ofthe individual with the virtual experience to a health care provider.26. The system of claim 24, wherein the means for presenting theprescription for engagement of the individual with the virtualexperience to a third party comprises: means for selectively presentingthe prescription for engagement of the individual with the virtualexperience only to the individual.
 27. The system of claim 2, whereinthe means for accepting an indication of a prescribed schedule foradministration of the prescribed bioactive agent to an individual andmeans for presenting a prescription for engagement of the individualwith a virtual experience at at least one time when a concentration ofthe prescribed bioactive agent is expected to be below a substantiallyeffective level at least partly based on accepting the pharmacokineticprofile of the prescribed bioactive agent and at least partially basedon accepting the indication of the prescribed schedule foradministration of the prescribed bioactive agent to the individualcomprises: means for accepting the pharmacokinetic profile of immediaterelease oxycodone, means for accepting a prescribed administrationschedule of the immediate release oxycodone to an individual, and meansfor presenting a prescription for engagement of the individual with avirtual experience at times when the plasma concentration of theimmediate release oxycodone is expected to be below a substantiallyeffective level based on the pharmacokinetic profile of the immediaterelease oxycodone and the prescribed administration schedule of theimmediate release oxycodone.
 28. A system, comprising: circuitry foraccepting a pharmacokinetic profile of a prescribed bioactive agent;circuitry for accepting an indication of a prescribed schedule foradministration of the prescribed bioactive agent to an individual; andcircuitry for presenting a prescription for engagement of the individualwith a virtual experience at at least one time when a concentration ofthe prescribed bioactive agent is expected to be below a substantiallyeffective level at least partly based on accepting the pharmacokineticprofile of the prescribed bioactive agent and at least partially basedon accepting the indication of the prescribed schedule foradministration of the prescribed bioactive agent to the individual, thepharmacokinetic profile of the prescribed bioactive agent including atleast one or more effective concentration levels of the prescribedbioactive agent.
 29. A computer program product comprising: anon-transitory signal-bearing medium bearing one or more instructionsfor accepting a pharmacokinetic profile of a prescribed bioactive agent;one or more instructions for accepting an indication of a prescribedschedule for administration of the prescribed bioactive agent to anindividual; and one or more instructions for presenting a prescriptionfor engagement of the individual with a virtual experience at at leastone time when a concentration of the prescribed bioactive agent isexpected to be below a substantially effective level at least partlybased on accepting the pharmacokinetic profile of the prescribedbioactive agent and at least partially based on accepting the indicationof the prescribed schedule for administration of the prescribedbioactive agent to the individual, the pharmacokinetic profile of theprescribed bioactive agent including at least one or more effectiveconcentration levels of the prescribed bioactive agent.
 30. The computerprogram product of claim 29, wherein the signal-bearing medium includesa computer-readable medium.
 31. The computer program product of claim29, wherein the signal-bearing medium includes a recordable medium. 32.The computer program product of claim 29, wherein the signal-bearingmedium includes a communications medium.
 33. A system comprising: acomputing device; and one or more instructions that when executed on thecomputing device cause the computing device to at least: accept apharmacokinetic profile of a prescribed bioactive agent; accept anindication of a prescribed schedule for administration of the prescribedbioactive agent to an individual; and present a prescription forengagement of the individual with a virtual experience at at least onetime when a concentration of the prescribed bioactive agent is expectedto be below a substantially effective level at least partly based onaccepting the pharmacokinetic profile of the prescribed bioactive agentand at least partially based on accepting the indication of theprescribed schedule for administration of the prescribed bioactive agentto the individual, the pharmacokinetic profile of the prescribedbioactive agent including at least one or more effective concentrationlevels of the prescribed bioactive agent.
 34. The system of claim 33wherein the computing device comprises: one or more of a personaldigital assistant (PDA), a personal entertainment device, a mobilephone, a laptop computer, a tablet personal computer, a networkedcomputer, a computing system comprised of a cluster of processors, acomputing system comprised of a cluster of servers, a workstationcomputer, and/or a desktop computer.
 35. The system of claim 33, whereinthe computing device is operable to accept the at least one attribute ofthe at least one individual and present the indication of the at leastone prescription medication and the at least one virtual experience fromat least one memory.